US20130272986A1 - Antimicrobial compositions, products and methods employing same - Google Patents

Antimicrobial compositions, products and methods employing same Download PDF

Info

Publication number
US20130272986A1
US20130272986A1 US13/914,166 US201313914166A US2013272986A1 US 20130272986 A1 US20130272986 A1 US 20130272986A1 US 201313914166 A US201313914166 A US 201313914166A US 2013272986 A1 US2013272986 A1 US 2013272986A1
Authority
US
United States
Prior art keywords
composition
present
antimicrobial
acid
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/914,166
Inventor
Robert Ya-Lin Pan
Rosa Laura Moese
Abel Saud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/177,445 external-priority patent/US20040001797A1/en
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Priority to US13/914,166 priority Critical patent/US20130272986A1/en
Publication of US20130272986A1 publication Critical patent/US20130272986A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N41/00Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom
    • A01N41/02Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom containing a sulfur-to-oxygen double bond
    • A01N41/04Sulfonic acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/30Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/02Saturated carboxylic acids or thio analogues thereof; Derivatives thereof
    • A01N37/04Saturated carboxylic acids or thio analogues thereof; Derivatives thereof polybasic
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/36Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/44Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0208Tissues; Wipes; Patches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365Hydroxycarboxylic acids; Ketocarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/466Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00Anti-perspirants or body deodorants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005Antimicrobial preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/10Washing or bathing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/02Preparations for cleaning the hair
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to antimicrobial compositions, products incorporating said antimicrobial compositions and methods of using the present antimicrobial compositions and products. More specifically, the present invention relates to antimicrobial compositions comprising an organic acid or organic acid mixture, a specific, short-chain anionic surfactant having at least one of the following: a large, hydrophilic head group; an unsaturated structure; and/or a branched structure.
  • Bacteria found on human skin may be divided into two groups, namely, resident and transient bacteria.
  • Resident bacteria are Gram-positive bacteria that establish as permanent microcolonies on the surface and outermost layers of the skin. Such bacteria play a fundamental role in preventing the colonization of other, more harmful bacteria and fungi.
  • Transient bacteria are bacteria that are not part of the normal resident of the flora of the skin. Rather, transient bacteria are deposited when airborne contaminated material lands on the skin or when contaminated material is brought into physical contact with such bacteria.
  • Transient bacteria are typically divided into two subgroups: Gram-positive and Gram-negative.
  • Gram-positive bacteria include pathogens such as Staphylococcus aureus, Streptococcus pyogenes and Clostridium botulinum .
  • Gram-negative bacteria include pathogens such as Salmonella, Escherichia coli, Klebsiella, Haemophilus, Pseudomonas aeuginosa, Proteus and Shigella dysenteriae .
  • Gram-negative bacteria are generally distinguished from Gram-positive bacteria via the existence of an additional protective cell membrane in the former, which often results in Gram-negative bacteria being less susceptible to conventional, topical antibacterial actives.
  • antimicrobial cleansing products include deodorant soaps, hard surface cleaners, and surgical disinfectants. These traditional, rinse-off antimicrobial products have been formulated to provide bacteria removal during washing. A few such products, including antimicrobial soaps, have also been shown to provide a residual effectiveness against Gram-positive bacteria, but provide limited residual effectiveness against Gram-negative bacteria.
  • residual effectiveness it is meant that the subject antimicrobial controls microbial growth on a substrate by either preventing growth of microbes or engaging in continuous kill of microbes for some period of time following the washing and/or rinsing process.
  • those skilled in the art have sought to incorporate high levels of alcohol and/or harsh surfactants into contemporary antimicrobial products, which have been shown to cause dryness and irritation to skin tissues.
  • the present invention addresses and resolves all of the problems associated with the employment of conventional antimicrobial compositions and/or products. Indeed, it has been surprisingly discovered that a composition incorporating an organic acid or organic acid mixture, a specific short-chain anionic surfactant having at least one of a large, hydrophilic head group; an unsaturated structure; and/or a branched structure; constitutes a viable advancement and alternative in the realm of antimicrobial formulations.
  • the antimicrobial compositions of the present invention are adapted for direct application to human skin, without causing dryness or irritation.
  • the antimicrobial compositions of the present invention are designed for use with or without water, and provide immediate and residual effectiveness in either instance against a variety of viruses and bacteria, including rotavirus, rhinovirus, respiratory syncytial virus (RSV), coronavirus, Gram-positive and Gram-negative bacteria.
  • viruses and bacteria including rotavirus, rhinovirus, respiratory syncytial virus (RSV), coronavirus, Gram-positive and Gram-negative bacteria.
  • RSV respiratory syncytial virus
  • anionic surfactant of the present invention presents a particularly novel aspect of the present compositions.
  • Those of skill in the art have generally relied upon the incorporation of longer chain (i.e. C 12 to C 16 ) anionic surfactants into antimicrobial compositions.
  • Conventional surfactants comparable to the acyl components found in the phospholipid matrix of the cell membrane of bacteria and virus, are thought to possess optimum antimicrobial activity with reduced skin tissue penetration.
  • conventional anionic surfactants have been associated with low solubility under acidic conditions, poor compatibility with cationic antimicrobial agents, slow dissolution kinetics and limited residual antimicrobial performance.
  • the short chain anionic surfactants of the present invention comprise at least one of the following characteristics: a large, hydrophilic head group; an unsaturated structure; and/or a branched structure.
  • the surfactants of the present invention have traditionally been regarded as unsuitable for incorporation into an antimicrobial composition, based on the belief that such surfactants possess relatively low surface activity.
  • the surfactants of the present invention deliver enhanced antimicrobial efficacy against rotavirus, rhinovirus, respiratory syncytial virus (RSV), coronavirus, Gram-negative bacteria and Gram-positive bacteria.
  • RSV respiratory syncytial virus
  • the large head group, unsaturated structure and/or branched structure of the present surfactants reduces or limits their tendency to penetrate skin tissue, while maximizing the immediate and residual effectiveness of the antimicrobial compositions in which they are incorporated.
  • the anionic surfactants of the present invention exhibit stability in an aqueous product at a low pH, are compatible with cationic antimicrobial agents and convey strong residual antimicrobial activity when the substrate on which they are applied is later inoculated with virus or bacteria.
  • antimicrobial compositions comprising an organic acid or organic acid mixture, a specific, short-chain anionic surfactant mixture are disclosed.
  • suitable anionic surfactants for use in the context of the present invention comprise a chain length of from about C 4 to C 12 and at least one of the following characteristics: a large, hydrophilic head group; an unsaturated structure; and/or a branched structure.
  • the antimicrobial compositions disclosed herein optionally further comprise a calcium ion scavenger and/or an anti-foam agent.
  • the compositions of the present invention are adapted to provide immediate and residual kill of numerous bacteria and viruses, with or without the use of water and without causing dryness or irritation to skin.
  • products incorporating the antimicrobial compositions of the present invention are disclosed.
  • Such products may take an assortment of shapes and forms depending on the precise application for which deployment of the product is desired and the needs and/or abilities of the formulator.
  • the products of the present invention are effective in eradicating numerous bacteria and viruses, both immediately and residually and are adapted to prevent dryness and/or irritation to mammalian skin tissue.
  • methods of using the antimicrobial compositions and products of the present invention are disclosed.
  • the methods of the present invention are adapted to achieve immediate and/or residual kill of a variety of viruses and bacteria, without irritating the skin and with or without the use of water.
  • antimicrobial compositions adapted for immediate and residual efficacy against a variety of bacteria and viruses.
  • the compositions of the present invention comprise an organic acid or organic acid mixture; an anionic surfactant having a chain length of from about C 4 to about C 12 and at least one of the following characteristics: an unsaturated structure, a branched structure; and/or a hydrophilic head group having a total head group size (defined, infra) of between about 4 to about 15 Angstroms.
  • the antimicrobial compositions disclosed herein optionally further comprise a calcium ion scavenger and/or anti-foam agent.
  • the compositions of the present invention are characterized by a pH of between about 2.0 to about 4.5, depending on the specific constituents of the present antimicrobial compositions and the application for which their use is intended.
  • the antimicrobial compositions disclosed herein comprise an amount of an organic acid or organic acid mixture.
  • Organic acids for purposes of the present disclosure, are defined as proton-donating agents that remain at least partially undisassociated in a concentrated composition and remain so when the compositions are diluted during washing and rinsing.
  • the organic acids of the present invention serve to protonate the carboxylate functionalities on the phospho lipid membrane of bacteria and virus and reduce the tendency of the membrane to electronically repel anionic surfactants, thereby facilitating proper interaction between the present, anionic surfactants and the membrane.
  • the organic acids disclosed herein facilitate the creation of a low pH buffer on the surface of a substrate, thereby prolonging the residual antimicrobial activity of the compositions and products in which they are incorporated.
  • the present organic acids are added directly to the compositions of the present invention in acidic form or are formed by adding the conjugate base of the desired acid and an amount of a separate acid sufficient to form the undisassociated acid from the base.
  • the antimicrobial compositions of the present invention comprise from about 0.2% to about 70%, preferably about 0.5% to about 40%, more preferably from about 1.0% to about 30%, based on the total weight of the antimicrobial composition, of an organic acid or organic acid mixture.
  • Suitable organic acids of the present invention include, but certainly are not limited to: pyroglutamic acid, adipic acid, gluconic acid, glyconolactone acid, glutamic acid, glycolic acid, glutaric acid, tartaric acid, ascorbic acid, benzoic acid, salicylic acid, citric acid, malic acid, succinic acid, lactic acid, carboxymethylcellulose and mixtures thereof.
  • suitable organic acids for incorporation into the present compositions are characterized by a pKa of greater than about 3.0.
  • the pKa selection limitation of the present organic acids serves the fundamental goal of ensuring that at least 50% of the organic acids incorporated into the present compositions remain undisassociated at the desired pH of from about 2.0 to about 4.5 (discussed, infra).
  • the compositions disclosed herein comprise a calcium ion scavenger.
  • the calcium ion scavengers of the present invention facilitate the disruption of the cell membrane of bacteria and viruses by the present, anionic surfactants via capture of the calcium ions of the phospholipid cell membrane.
  • said calcium ions are believed to exist within and around the cell membrane, thereby often preventing the penetration of conventional surfactants.
  • the present, calcium ion scavengers are a particularly preferred ingredient of the present antimicrobial compositions when the targeted microbial is rotavirus.
  • Suitable calcium ion scavengers of the present invention include, but are not limited to: citric acid, malic acid, succinic acid, polyacrylic acid, copolymers of acrylic acid and maleic acid, oxydisuccinic acid, nitrilotriacetic acid, iminodisuccinic acid, tartrate disuccinic acid, tartrate monosuccinic acid, ethylenediaminetetraacetic acid, pyrophosphoric acid and mixtures thereof.
  • the calcium ion scavengers of the present invention are characterized by a pKa of lower than about 3.0.
  • suitable calcium ion scavengers are characterized by a calcium ion binding constant (log P) of greater than about 3.0 at a pH of about 3.
  • anionic surfactants of the present invention constitute a particularly novel and unobvious aspect of the present invention. Indeed, it has been surprisingly discovered that, contrary to the conventional wisdom in the art, anionic surfactants having a chain length of from about C 4 to about C 12 and at least one characteristic selected from: a large hydrophilic head group; an unsaturated structure; and/or a branched structure; provide enhanced performance benefits, while minimizing dryness and/or irritation to mammalian skin tissue.
  • the short chain anionic surfactants of the present invention exhibit phase stability in formulation, compatibility with other antimicrobial agents and residual efficacy of the antimicrobial compositions in which they are incorporated.
  • the antimicrobial compositions of the present invention comprise from about 0.1% to about 40%, preferably from about 0.2% to about 30%, more preferably from about 0.3% to about 20% of an anionic surfactant mixture.
  • the short-chain anionic surfactants disclosed herein are incorporated into the present, antimicrobial compositions at a level of greater than about 25%.
  • the anionic surfactants useful for incorporation into the present antimicrobial compositions comprise a relatively short carbon chain, preferably between about C 4 to about C 12 , more preferably between about C 6 to about C 11 , most preferably between about C 6 to about C 10 .
  • the average chain length of the resultant anionic surfactant mixture may differ from the above-described ranges.
  • short-chain anionic surfactants are characterized by decreased interfacial activity and decreased interaction with the phospholipid membrane of bacteria and virus, and thus, provide poor microbiocidal activity. Accordingly, those of skill in the art have generally relied upon the employment of anionic surfactants with chain lengths of from C 12 to C 16 in antimicrobial compositions. The chain lengths of such surfactants are comparable to those of the acyl components in the phospholipid membrane of bacteria and virus, and thus, are thought to provide optimum microbiocidal activity.
  • longer chain surfactants have conventionally been thought to be less capable of skin penetration, and thus, less likely to cause dryness and irritation to skin. Nevertheless, conventional, longer chain anionic surfactants often exhibit poor phase stability in an acidic product matrix, incompatibility with cationic antimicrobial agents and decreased residual antimicrobial activity. Conversely, the shorter chain anionic surfactants of the present invention exhibit surprisingly high immediate microbiocidal activity, phase stability in broad concentration ranges of acidic aqueous matrices and compatibility with cationic antimicrobial agents. Importantly, the anionic surfactants of the present invention prevent dryness or irritation to skin and demonstrate strong residual microbiocidal activity on a target substrate when the substrate is later inoculated with bacteria or virus.
  • the short chain anionic surfactants disclosed herein possess an unsaturated structure and/or a branched, hydrophobic group with a total carbon content ranging from about C 4 to about C 12 , preferably from about C 6 to about C 11 and more preferably from about C 6 to
  • the short-chain anionic surfactants disclosed herein comprise a hydrophilic head group with a total head group size of less than about 15 Angstroms, preferably less than about 10 Angstroms, more preferably between about 4 to about 7 Angstroms.
  • total head group size it is meant the accumulated size of every substituent on the hydrophilic head group of the present anionic surfactants.
  • the present anionic surfactants may comprise more than one substituent on their subject hydrophilic head groups, for a combined, total hydrophilic head group size falling within the above-listed, ranges.
  • the unsaturated structure and/or branched structure and/or large hydrophilic head group of the present, anionic surfactants increases their water solubility, increases their compatibility with cationic agents, increases steric hindrance to their disruption of the stratum conium layer of skin and maintains their substantivity to the phospholipid membrane of bacteria and viruses.
  • the “hydrophilic head group” is defined as the hydrophilic portion (which may contain both non-hydrocarbon and hydrocarbon units) of the anionic surfactant, measured from the first polar atom to the end of the hydrophilic segment that links to the hydrophobic body.
  • the hydrophilic head group of alkyl glyceryl sulfonate R—O—CH 2 CH(OH)CH 2 —SO 3 Na is —O—CH 2 CH(OH)CH 2 —SO 3 Na.
  • the hydrophilic head group size is estimated from the Van der Waals radius of the atoms and the configuration of the surfactant molecule.
  • Suitable hydrophilic head groups of the present invention with a size of less than about 10 Angstroms include, but are not limited to: glyceryl ether sulfonates and, for compositions having a pH of greater than 3.5, isethionates, sulfosuccinates, amidosulfonates and ethoxylated sulfonates.
  • the head group of the anionic surfactant is characterized by substitution of one or more substituents.
  • substituents it is meant any hydrophilic segment that is bonded to the head group, defined hereinbefore, of the present anionic surfactants. Without wishing to be bound by theory, it is believed that such increased substitution on the head group of the present anionic surfactants further increases the size and hydrophilicity of the head group.
  • Suitable hydrophilic head groups of the present invention with multiple substituents include, but are not limited to, alpha sulfo fatty acid, and if the pH of the present antimicrobial compositions is greater than 3.5, monoester of sulfosuccinic acid.
  • head group size of the present anionic surfactants is defined on the basis of Angstroms, as discussed supra.
  • the hydrophilic head group of the present anionic surfactants may comprise more than one substituent, the total hydrophilic head group size should not exceed the preferred size ranges, set forth hereinbefore, in Angstroms.
  • suitable anionic surfactants of the present invention include, but certainly are not limited to: linear or branched alkyl glyceryl sulfonate, alkyl alpha sulfo fatty acid, alpha olefin sulfonate, branched alkyl sulfonate, branched alkyl benzene sulfonate, branched alkyl phosphonate and if the pH of the antimicrobial composition is greater than about 3.5, secondary alkyl sulfate, alkyl isethionate, monoester of alkyl sulfosuccinic acid, alkyl aminosulfonate, alkyl ethoxylated sulfonate, and combinations thereof.
  • anionic surfactants having a chain length of from about C 4 to about C 12 and comprising at least one of the following characteristics are suitable for use herein: an unsaturated structure; a branched structure and/or a hydrophilic head group size as described hereinbefore. Selection of the appropriate anionic surfactant for use in the antimicrobial compositions of the present invention will depend upon the needs and/or abilities of the formulator. In another aspect of the present invention, other surfactants, many commercially available, are incorporated into the antimicrobial compositions of the present invention.
  • Said surfactants although depending on the precise form of the desired antimicrobial composition, include, but certainly are not limited to: paraffin sulfonate, hydrolyzed methyl ester sulfonate, alkyl sulfosuccinate, alkyl glyceryl sulfonate, alpha olefin sulfonate, alkyl isethionate, secondary alkyl sulfate, branched alkyl benzene sulfonate, alkyl sulfate and combinations thereof.
  • anionic surfactant for use in the context of the antimicrobial compositions of the present invention will depend upon several factors, including, but certainly not limited to: the nature of the substrate for which use of the antimicrobial compositions disclosed herein is desired and the needs and/or abilities of the formulator and/or practitioner of the present compositions.
  • short chain anionic surfactants having a hydrophilic head group size of less than about than 4 Angstroms and/or a linear structure may be suitable for use in the context of the present invention.
  • suitable anionic surfactants for use in the context of the present invention include, but certainly are not limited to: sulfonates and sulfates having a linear chain with a chain length of from about C 4 to about C 12 , preferably having a chain length of from about C 6 to about C 12 , more preferably having a chain length of from about C 8 to about C 12 .
  • the antimicrobial compositions disclosed herein comprise an anti-foam or suds suppression agent. Incorporation of said agents is particularly desired for applications in which the present antimicrobial compositions comprise high sudsing, short chain anionic surfactants such as alkyl glyceryl sulfonate and/or a level of anionic surfactant of greater than about 1 weight percent. Incorporation of an anti-foam agent or suds suppression system is further advantageous in compositions for which low foaming is desired, particularly when such foaming has the affect of decreasing the conveyance of antimicrobial dosage.
  • the antimicrobial compositions disclosed herein comprise an anti-foam or suds suppression agent, present at a level of from about 0.0001% to about 15%, preferably from about 0.001% to about 10%, most preferably from about 0.005% to about 5% by weight of the antimicrobial composition.
  • the anti-foam agent is present in an amount of at least 1 ppm by weight of the total composition.
  • suitable suds suppressing systems for use herein may comprise essentially any known antifoam compound that exhibits stability at a pH of about 2.0 to about 4.5, including, but not limited to, those selected from the group consisting of: silicone antifoam compounds, silicone emulsions, 2-alkyl and alkanol antifoam compounds, mineral oil emulsions, hydrocarbon oil emulsions, polyalkylene emulsions and combinations thereof.
  • Silicone suds suppressor technologies and other anti-foam agents useful herein are extensively documented in “Defoaming, Theory and Industrial Applications”, Ed., P. R. Garrett, Marcel Dekker, N.Y., 1973, ISBN 0-8247-8770-6, incorporated herein by reference. See especially the chapter “Surfactant Antifoams” (Blease et al). See also U.S. Pat. Nos. 3,933,672 and 4,136,045, both incorporated herein by reference.
  • Highly preferred silicone suds suppressors are the compounded types known for use in antimicrobial compositions, including, for example, polydimethylsiloxanes having trimethylsilyl or alternate endblocking units.
  • Such compounds may be compounded with silica and/or with surface-active nonsilicon components, as illustrated by a suds suppressor comprising 12% silicone/silica, 18% stearyl alcohol and 70% starch.
  • a suitable, commercial source of the silicone active compounds is Dow Corning Corp.
  • the antimicrobial compositions disclosed herein further comprise a nonionic agent.
  • suitable nonionic agents for use in the present compositions are selected from the group consisting of: alkyl polyols, alkyl alcohols, phenols, chloro phenols, polyphenols and mixtures thereof.
  • the optional nonionic agent of the present invention serves many roles, including, but certainly not limited to, increasing the antibacterial efficacy, in both immediate and residual kill, of the organic acid and short chain anionic surfactant system of the present invention.
  • alkyl polyols such as 1-(2-ethylhexyl)glycerol ether
  • alkyl polyols and alkyl alcohols have the affect of increasing the immediate and residual activity of the present compositions.
  • the nonionic agents of the present invention are incorporated into the present antimicrobial compositions in an amount of from about 0.1% to about 10%, preferably from about 0.1% to about 5%, more preferably from about 0.1% to about 3%, by weight of the total, antimicrobial composition.
  • the antimicrobial compositions of the present invention comprise a nonionic agent
  • said agent comprises a carbon chain length of from about C 3 to about C 12 .
  • Suitable nonionic agents for incorporation into the antimicrobial compositions of the present invention include, but certainly are not limited to: 1-(2-ethylhexyl)glycerol ether, octyl glycerol ether, 2-(2-ethylhexylxoxy)propanol, octyloxy propanol, 1-(2-ethylhexyloxy)ethanol, octyloxy ethanol, 1,2 hexylenediol, 1,2-cyclohexanedimethanol, isopropyl glycerol ether, 4-chloro-3-xylenol and combinations thereof.
  • the nonionic agent is branched, unsaturated or linear.
  • the nonionic agent is substituted with compounds selected from the group consisting of: alcohols, polyols, phenols, chloro phenols, polyphenols and combinations thereof.
  • compositions disclosed herein will comprise one or more adjunct ingredients. Said ingredients may be employed to increase the mildness of the desired composition, increase immediate and/or residual efficacy of the subject compositions, improve the wetting characteristics of the subject compositions upon application to a target substrate, operate as solvents for diluted compositions, and/or serve to modify the aesthetic characteristics of the composition.
  • the compositions disclosed herein comprise from about 0% to about 70%, preferably from about 0% to about 62%, more preferably from about 0% to about 10%, of an alcohol solvent. Suitable alcohol solvents of the present invention include, but are not limited to, ethanol, propanol, butanol, propylene glycol, diethylene glycol, dipropylene glycol and mixtures thereof.
  • compositions disclosed herein comprise from about 0% to about 10%, preferably from about 0% to about 5%, more preferably from about 0% to about 1%, of a cationic antimicrobial agent.
  • a cationic antimicrobial agent e.g., benzalkonium chloride, benzethonium chloride, triclocarban, tricolsan, chlorhexidine and mixtures thereof.
  • the compositions disclosed herein comprise from about 0% to about 5%, preferably from about 0% to about 2%, of a heavy metal salt selected from the group consisting of: silver, zinc, copper and mixtures thereof. Incorporation of said heavy metal salt serves to increase the antimicrobial activity and the viscosity of the present, antimicrobial compositions. Moreover, the other ingredients of the present compositions have exhibited compatibility with the heavy metal salts disclosed herein.
  • the compositions disclosed herein comprise from about 0% to about 20%, preferably from about 0% to about 5%, of a skin emollient or moisturizer. Such ingredients serve the fundamental purpose of increasing the mildness (discussed infra) of the present antimicrobial compositions and are particularly desired when incorporating the present antimicrobial compositions into a skin care product (discussed infra).
  • one or more adjunct ingredients are incorporated into the antimicrobial compositions disclosed herein, to facilitate formulation of the desired composition.
  • additional adjunct ingredients is often necessary to formulate certain ingredients included in the present compositions and in antimicrobial compositions generally. Indeed, it has been discovered, and documented via the present disclosure, that the formulation of certain perfumes and/or skin emollients in antimicrobial compositions requires the use of alkyl polyether-type emulsifiers. It has been learned that the use of said alkyl polyether-type emulsifiers is necessary to achieve physical stability of the resultant antimicrobial product when attempting to formulate certain perfumes and/or skin emollients.
  • emulsifiers are commercially available and often used in the context of formulation of antimicrobial-type compositions, the inventors of the subject matter disclosed herein have discovered that the use of emulsifiers other than those of the alkyl polyether-type, results in a chemically instable, yet efficacious, end product.
  • the antimicrobial compositions disclosed herein comprise from about 0.05% to about 5%, preferably from about 0.1% to about 1%, more preferably from about 0.2% to about 0.5% of an alkyl polyether-type emulsifier.
  • alkyl polyether-type emulsifiers suitable for incorporation into the antimicrobial compositions disclosed herein include: isoceteth-20 (CAS No. 69364-63-2) and ceteth-20 (CAS No. 9004-95-9).
  • alkyl polyether-type emulsifiers disclosed herein are provided for use in the context of formulation of any antimicrobial composition comprising one or more otherwise physically instable adjunct ingredients, and not specifically limited to the antimicrobial compositions disclosed herein.
  • said otherwise physically instable adjunct ingredients include, but certainly are not limited to: perfumes, skin emollients, other nonionic agents and mixtures thereof.
  • the present invention further seeks to encompass the use of sulfonate anionic surfactant having a chain length of C 12 to C 18 are suitable for use in the context of the antimicrobial compositions disclosed herein, and are particularly preferred when the formulator of the present compositions seeks to incorporate certain adjuncts such as perfumes, skin emollients and combinations thereof.
  • the antimicrobial compositions disclosed herein comprise from about 0 to about 5%, preferably from about 0.1% to about 2%, more preferably from about 0.2% to about 1%.
  • Suitable sulfonate anionic surfactants for use in the context of the present invention include, but certainly are not limited to: C 14-18 paraffin sulfonate and C 14-18 alkyl alpha olefin sulfonate.
  • the incorporation of sulfonate anionic surfactants is particularly preferred in the context of the present invention when the formulator of the present compositions seeks to include perfumes, skin emollients and combinations thereof.
  • the pH of the antimicrobial compositions of the present invention must be adjusted to a sufficiently low level in order to either form or deposit substantially undisassociated acids onto the substrate for which treatment is desired.
  • substantially undisassociated it is meant that, upon application of the present compositions onto a target substrate, such as mammalian skin, about 30%, preferably 50%, more preferably 70%, of the organic acids incorporated in said compositions remain undisassociated following the elapse of about 30 minutes from application.
  • the pH of the present compositions should be adjusted and preferably buffered to achieve the desired range.
  • the antimicrobial compositions disclosed herein are characterized by a pH of from about 2.0 to about 4.5, preferably from about 2.5 to about 4.0.
  • the pH of the antimicrobial compositions of the present invention will depend upon the precise ingredients incorporated into the subject compositions. Nevertheless, the pH of the present compositions is generally, and preferably, above about 2.0, as compositions characterized by a pH below 2.0 are typically required to be identified as toxic or hazardous materials.
  • Topically applied products including rinse-off cleansers and leave-on sanitizers, have conventionally possessed the tendency to irritate or dry mammalian skin.
  • the compositions of the present invention provide immediate and residual kill of bacteria and viruses, while possessing the fundamental characteristic of mildness.
  • mildness it is meant the degree to which a composition prevents dryness or irritation to skin.
  • Factors that influence the mildness of a topically applied antimicrobial product include, but are not limited to, duration of exposure to the product, the frequency of use of the product and the degree to which the skin is occluded following exposure to the product.
  • Irritation is observed by several methods, including but not limited to, visual and instrumental assessment of the erythema for redness and of the skin for edema following application of an antimicrobial product. Irritation may be measured by determining the transepidermal water loss (TEWL) of skin before and after exposure to an antimicrobial product, using, for example, a TEWL meter. Indeed, products that cause irritation may eventually compromise the natural barrier function of mammalian skin—resulting in increased water loss through the epidermis. Dryness is observed by several methods including, but not limited to, visual and instrumental assessment of the level and severity of dry skin flakes following exposure to an antimicrobial product. Dryness may be measured by instruments that examine the water content of the skin. One such instrument, a corneometer, measures the water content of skin via capacitance.
  • a corneometer measures the water content of skin via capacitance.
  • the present invention despite its enormous cleaning and antimicrobial characteristics, is adapted to ensure increased mildness to mammalian skin upon application, particularly when compared to conventional cleansers such as bar or liquid soap and leave-on sanitizers.
  • conventional cleansers such as bar or liquid soap and leave-on sanitizers.
  • the efficacy and mildness of the compositions of the present invention has been examined and illustrated under a variety of use conditions and methods. Namely, during a 10-day clinical forearm study, subjects applying the compositions of the present invention experienced significantly less skin irritation and dryness than subjects engaging in the same number of washes per day with soap and water and subjects applying conventional alcohol-based hand sanitizers. The results of the aforementioned study were measured using both visual and instrumental methods.
  • the 10-day clinical forearm study is intended to mirror the hand washing and/or sanitizer use frequency typically recommended for proper hygiene.
  • the leave-on application of the present compositions was applied 4 times daily, in addition to normal hand washing, and resulted in no measurable skin irritation or dryness.
  • the present invention further relates to products that comprise the antimicrobial compositions of the present invention, as well as combinations of such products. Indeed, the combined and systematic use of products containing the antimicrobial compositions of the present invention serves to eradicate viruses (e.g. rhinovirus, rotavirus, respiratory syn ⁇ cytial virus (RSV), coronavirus) and bacteria (e.g. Gram-positive and Gram-negative) for a longer period of time and prevent their spread.
  • viruses e.g. rhinovirus, rotavirus, respiratory syn ⁇ cytial virus (RSV), coronavirus
  • bacteria e.g. Gram-positive and Gram-negative
  • Suitable personal care products comprising the antimicrobial compositions of the present invention include, but are not limited to: hand soaps, hand sanitizers, body washes, mouth washes, toothpastes, shower gels, shampoos, body lotions, deodorants, nasal sprays, foot care, vaginal care and/or wash, pet care and combinations thereof.
  • the personal care products disclosed herein take the form of a wipe product, particularly suitable for wiping or drying the face or hands.
  • the antimicrobial compositions of the present invention are preferably embedded or impregnated into said wipe product.
  • the personal care product disclosed herein takes the form of a tissue or towel, also suitable for wiping or drying the face or hands.
  • the personal care product takes the form of a feminine napkin and/or a diaper.
  • the personal care product takes the form of a first aid antiseptic for irritated, injured, or acne-affected skin and/or for pre or post surgical use.
  • the antimicrobial compositions of the present invention are incorporated into one or more household care products.
  • suitable household care products for purposes of the present invention include, but are not limited to: hard surface cleaners, deodorizers, fabric care compositions, fabric cleaning compositions, manual dish detergents, automatic dish detergents, floor care compositions, kitchen cleaners or disinfectants, bathroom cleaners or disinfectants and combinations thereof.
  • the household care product takes the form of a wipe or towel, suitable for household cleaning and/or care.
  • the household care products disclosed herein comprise certain adjunct ingredients.
  • Said adjuncts include, but certainly are not limited to: detersive enzymes, builders, bleaching agents, bleach activators, transitional metal bleach catalysts, oxygen transfer agents and precursors, soil release agents, clay soil removal and/or anti-redeposition agents, polymeric dispersing agents, brightener, polymeric dye transfer inhibiting agents, chelating agents, anti-foam agents, alkoxylated polycarboxylates, fabric softeners, perfumes, carriers, hydrotropes, processing aids, dyes or pigments, solvents for liquid formulations, solid fillers, detersive surfactants and combinations thereof.
  • the antimicrobial compositions of the present invention are incorporated into a skin care product.
  • the skin care product incorporates a dermatologically acceptable carrier to facilitate safe transfer of the antimicrobial composition of the present invention to the desired area of the skin.
  • the skin care product of the present invention comprises certain adjunct ingredients.
  • Said adjuncts include, but certainly are not limited to: antimicrobial and antifungal actives, surfactants, desquamation actives, anti-acne actives, anti-wrinkle actives, anti-atrophy actives, anti-oxidants, radical scavengers, chelators, flavonoids, anti-inflammatory agents, anti-cellulite agents, topical anesthetics, tanning actives, sunscreen actives, conditioning agents, thickening agents, detackifying agents, odor control agents, skin sensates, antiperspirants and mixtures thereof.
  • antimicrobial and antifungal actives include, but certainly are not limited to: antimicrobial and antifungal actives, surfactants, desquamation actives, anti-acne actives, anti-wrinkle actives, anti-atrophy actives, anti-oxidants, radical scavengers, chelators, flavonoids, anti-inflammatory agents, anti-cellulite agents, topical anesthetics, tanning actives, sunscreen actives
  • articles of manufacture comprising the antimicrobial compositions of the present invention and/or one or more of the aforementioned products, are intended for personal care, skin care and household care applications.
  • the article of manufacture of the present invention encompasses one or more products as described hereinbefore that may be packaged in a container or dispenser with a set of instructions for the consumer.
  • the article of manufacture of the present invention typically comprises (a) container or dispenser, (b) product and (c) set of instructions to apply said product to an appropriate substrate to achieve immediate and residual antimicrobial activity.
  • Containers and/or dispensers suitable for the article of manufacture of the present invention include, but are not limited to: PET bottles and tubs, flow-wrap pouches, foaming dispensers, spray dispensers and combinations thereof.
  • the article of manufacture of the present invention further comprises a set of instructions in association with the container.
  • association with it is meant that the instructions are either directly printed on the container or dispenser itself or presented in a different fashion including, but not limited to: a brochure, print advertisement, electronic advertisement and/or verbal communication, so as to communicate the set of the instructions to a consumer of the article of manufacture.
  • the set of instructions typically comprise the instructions relating to the use of the product to apply the antimicrobial composition of the present invention onto a suitable substrate for which treatment is sought.
  • the set of instructions may further comprise the instruction to allow the antimicrobial composition of the present invention to remain on the treated substrate, without rinsing or otherwise removing the antimicrobial composition from the treated substrate.
  • the precise instructions included with the article of manufacture of the present invention will depend on the precise ingredients of the subject antimicrobial composition and the product for which the inclusion of instructions is desired and the substrate onto which application of the product is intended.
  • the instructions included in the present articles of manufacture coincide with the methods set forth in the “Methods of Use” section of the present disclosure.
  • the antimicrobial compositions and products of the present invention are suitable for a variety of uses. Indeed, suitable uses of the present compositions include, but certainly are not limited to, the eradication of viruses and/or bacteria; the provision of residual anti-viral efficacy; the provision of residual antibacterial efficacy; the prevention and/or treatment of a common cold or associated respiratory disease in a mammal; the prevention and/or treatment of a diarrhea disease in a mammal; the prevention and/or treatment of bacteria-related diseases in mammals resulting from contact with a bacteria-infected surface; the sanitization of hard surfaces; the improvement of the overall health of a mammal; the reduction of absenteeism; the prevention and/or treatment of dandruff and acne; and combinations thereof.
  • treatment with the compositions and products disclosed herein is effective when the cold or respiratory disease is caused by rhinovirus, coronavirus or RSV. It should be noted that, in the case of diarrhea, treatment with the present compositions and/or products is effective when the diarrhea is caused by rotavirus or bacteria.
  • a method of killing bacteria comprises the steps of topically applying the composition and/or product of the present invention to an area in need of treatment and, optionally, removing said composition and/or product following application.
  • a method of inactivating viruses is disclosed. Said method, too, comprises the steps of topically applying the composition and/or product of the present invention to an area in need of treatment and, optionally, removing said composition and/or product following application.
  • the method of inactivating viruses is useful in treating viruses selected from the group consisting of: rotavirus, rhinovirus and combinations thereof.
  • a method of providing residual antibacterial and antiviral efficacy preferably comprises the steps of topically applying the composition and/or product of the present invention to an area in need of treatment and, optionally, removing said composition following application.
  • a method of preventing and/or treating a respiratory disease or diarrhea in a mammal where the sickness is caused by a rhinovirus, coronavirus, RSV or rotavirus; respectively is envisioned.
  • Said method comprises the steps of topically applying the composition and/or products of the present invention to an area of the mammal in need of treatment and, optionally, removing said composition and/or product following application.
  • the present invention seeks to encompass a method of preventing and/or treating bacteria-related diseases in a mammal that result from said mammal's contact with a bacteria-infected substrate.
  • Said method comprises the steps of topically applying the composition and/or product of the present invention to an area of the mammal that is infected with said bacteria and, optionally, removing said composition and/or product following application.
  • each of the methods of the present invention comprise the step of topically applying a composition or product comprising same to an area or surface in need of treatment.
  • areas and/or surfaces in need of treatment, against which the compositions of the present invention are effective include, but are not limited to: one or more hands, a nose, a nasal canal or passage, an article of clothing, a hard surface, irritated, acne-affected, or injured skin, pre or post surgical areas and combinations thereof.
  • the antimicrobial compositions or products of the present invention are topically applied to keratinous tissue, e.g. adult hands, they are applied in doses of from about 0.1 mL to about 5 mL per use, more preferably 0.5 mL to about 4 mL, most preferably from about 1 mL to about 3 mL.
  • the compositions and products of the present invention are topically applied to surfaces in need of treatment from about 2 to about 6 times daily. Once applied, the compositions are rubbed on the treated surfaces for a period of time to ensure coverage, typically at least 5 seconds, preferably at least 10 seconds, more preferably at least 20 seconds and most preferably at least 30 seconds.
  • Example 12 and 16 relate to the preparation of a concentrated version of the antimicrobial compositions of the present invention.
  • the product solution of Examples 1 to 12 in Table 1 changed opacity from clear to hazy over time, due to the slow hydrolysis of hydrogenated castor oil.
  • the antimicrobial efficacy of the solutions included therein remained unaffected.
  • Examples 13 to 16 in Table 2 remained stable as clear aqueous solutions with consistent antimicrobial performance after prolonged storage under stressed conditions (e.g. one month at 45 degree C.).
  • Tables 3 to 6 summarize the efficacy of a few examples, the preparation of which is summarized in Tables 1 and 2.
  • the following disclosure further includes a discussion of the testing methods and results of the compositions disclosed herein, as well as methods for preparing one or more products in accordance with the present invention.
  • test bacteria suspension 10 ⁇ L was spread on mammalian skin and allowed to air dry for one minute, then 20 ⁇ L of the active solution was spread evenly over the treated skin and the preparation was allowed to rest uncovered for five minutes.
  • the skin substrate was placed into a test tube containing 10 mL of extraction solution (Phosphate buffer with Triton X-100, Lecithin and Tween) and vortex for 30 seconds.
  • a 50 ⁇ L aliquot was dispensed (via Spiral Biotech Autoplater) onto Trypticase Soy Agar+1.5% Tween 80 plates and viability was determined after 18 hours of incubation at 37° C. (CUF/ml)
  • test bacteria suspension (TSB) culture with a density of 1.0E+09 CFUs/ml was mixed with 5 ml of the active solution. After one minute time, the inoculated solution was mixed with DE neutralizing broth (ratio 1:10). A 50-4 aliquot was dispensed via Spiral Biotech Autoplater onto a Trypticase Soy Agar plate. Viability was determined after 18 hours of incubation at 37° C. (CUF/ml)
  • test virus suspension 10 ⁇ L was spread on the skin substrate and allowed to air dry at room temperature then 25 ⁇ L of the active solution was spread evenly over the treated skin and the preparation was allowed to rest for five minutes. Following the exposure period, a sterile 1.5 ml cryovial containing 1.0 ml of elution medium was inverted over the sink substrate surface and extraction was performed. The solution was mixed and serial 10 fold dilution was performed. The dilutions were assayed for the presence of virus in a host system. The virus titer of the stock was determined by the median cell culture infective dose (TCID 50). Cytotoxicity to the host system (active solution) at tested concentrations was also determined. The virus-product mixture was assayed in numerous units of the host system. Median values of log 10 virus inactivation were calculated.
  • MST Microbial Susceptibly Test
  • a test wipe was inoculated with 1.0 ml of virus suspension to cover one quarter of the folded wipe. 5 minutes after inoculation the treated wipe was placed into a sterile bag containing 100 ml of DE neutralizer medium, the bag was sealed and placed in the Stomacher for 2 minutes. After blending, a 50 ⁇ L it aliquot was dispensed (via Spiral Biotech Autoplater) onto Trypticase Soy Agar+1.5% Tween 80 plates and viability was determined after 18 hours of incubation at 37° C. (CUF/ml)
  • the liquid composition produced in accordance with the previous section may be packaged in a typical PET bottle with a flip-top cap. Liquid is dispensed to the hands in an amount to ensure complete wetting. Employing this method delivers immediate microbial kill and, upon drying, provides prolonged, residual activity.
  • the lotion produced in accordance with the previous section may be used to produce a wet wipe product for topical cleaning and/or sanitizing of skin and/or hard surfaces.
  • a wet wipe product for topical cleaning and/or sanitizing of skin and/or hard surfaces.
  • Such a product is made by saturating a paper or cloth substrate with the liquid composition prepared in accordance with the previous section. The level of saturation depends upon the substrate in which incorporation of the antimicrobial composition is desired.
  • a 5′′ ⁇ 8′′ hand wipe towelette made from 40-60 grams per square meter spun-lace non-woven material may be saturated with about 1-3 grams of liquid composition.
  • the liquid may be applied to the substrate via spraying and/or soaking prior to final packaging.
  • the wipe may be wrapped in single use pouches made from foil or plastic or packed in groups of 10, 40, or more in multiple use tubs.
  • the wipe is removed from its package and is rubbed onto the target surface, in a manner that ensures complete wetting of the surface.
  • the wetting practice removes visible dirt and eradicates bacteria and viruses. Upon drying, the surface experiences residual antimicrobial activity for several hours.
  • the lotion produced in accordance with the previous section may be used to produce a dry towel product for topical cleaning and/or sanitizing of skin or hard surfaces.
  • a dry towel product for topical cleaning and/or sanitizing of skin or hard surfaces.
  • Such a product is made by saturating a paper or cloth substrate with the liquid prepared in accordance with the preceding section. The substrate is then dried to remove all water. The level of saturation depends upon the substrate in which incorporation of the antimicrobial composition is desired.
  • a 5′′ ⁇ 8′′ towel made from 40-60 grams per square meter spun-lace non-woven material may be saturated with about 1-3 grams of liquid.
  • the liquid may be applied to the substrate via spraying and/or soaking prior to final packaging.
  • the liquid may also be applied in concentrate form using printing techniques employed in the color design of commercial, paper towels.
  • the towel may then be rolled or inserted into boxes.
  • the towel is applied to any wet skin or hard surface to dry it.
  • the water activates the antimicrobial properties of the composition within the towel, which is then imparted onto the surface.
  • the towel dries the target surface, removes visible dirt, delivers antimicrobial kill and provides prolonged, residual activity.
  • the antimicrobial compositions, methods and products of the present invention have demonstrated surprising anti-inflammatory benefits in the topical treatment of inflammation or dermatitis.
  • In vitro studies of the present invention and its key components have been conducted to assess the efficacy of the claimed compositions in inhibiting the cycloxygenase (COX) 1 and 2 enzymes.
  • Said enzymes are adapted to convert arachidonic acid in cell membranes to prostaglandin, a messenger agent that conveys a signal to the cells to increase and enhance their inflammatory response.
  • the results of the aforementioned in vitro study demonstrate that the present invention can significantly reduce the activity of both COX 1 and 2 enzymes.

Abstract

Antimicrobial compositions that provide enhanced immediate and residual anti-viral and antibacterial efficacy against rhinovirus, rotavirus, coronovirus, respiratory syncytial virus, Gram-positive bacteria, Gram-negative bacteria and combinations thereof. More specifically, antimicrobial compositions comprising an organic acid or organic acid mixture and a short-chain anionic surfactant having at least one of a large head group; a branched alkyl chain and an unsaturated alkyl chain. Further, products incorporating the antimicrobial compositions of the present invention and methods of using the antimicrobial compositions and products are disclosed herein.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of application Ser. No. 12/410,219, filed on 24 Mar. 2009, which is a continuation of application Ser. No. 10/600,180, filed on 20 Jun. 2003, which is a continuation-in-part of application Ser. No. 10/177,445, filed on 21 Jun. 2002 and application Ser. No. 10/263,211, filed on 2 Oct. 2002, both of which are abandoned.
  • FIELD OF THE INVENTION
  • The present invention relates to antimicrobial compositions, products incorporating said antimicrobial compositions and methods of using the present antimicrobial compositions and products. More specifically, the present invention relates to antimicrobial compositions comprising an organic acid or organic acid mixture, a specific, short-chain anionic surfactant having at least one of the following: a large, hydrophilic head group; an unsaturated structure; and/or a branched structure.
  • BACKGROUND OF THE INVENTION
  • Human and mammalian health is certainly impacted by the spread of microbial entities at home, school, work and in the environment generally. Indeed, viruses and bacteria continue to cause a variety of sicknesses and ailments, prompting high absenteeism in schools and places of employment. In the wake of widespread food poisoning and the like, the public has become even further concerned with sanitization, both of person and property. Consequently, those of skill in the art have focused their research endeavors on the identification and deployment of suitable antimicrobial compositions, and specifically those that provide immediate and residual kill of microbes, with or without the use of water.
  • A comprehension of the vast benefits achieved via practice of the present invention requires an understanding of the various microbes against which the present compositions are effective. Bacteria found on human skin may be divided into two groups, namely, resident and transient bacteria. Resident bacteria are Gram-positive bacteria that establish as permanent microcolonies on the surface and outermost layers of the skin. Such bacteria play a fundamental role in preventing the colonization of other, more harmful bacteria and fungi. Transient bacteria are bacteria that are not part of the normal resident of the flora of the skin. Rather, transient bacteria are deposited when airborne contaminated material lands on the skin or when contaminated material is brought into physical contact with such bacteria. Transient bacteria are typically divided into two subgroups: Gram-positive and Gram-negative. Gram-positive bacteria include pathogens such as Staphylococcus aureus, Streptococcus pyogenes and Clostridium botulinum. Gram-negative bacteria include pathogens such as Salmonella, Escherichia coli, Klebsiella, Haemophilus, Pseudomonas aeuginosa, Proteus and Shigella dysenteriae. Gram-negative bacteria are generally distinguished from Gram-positive bacteria via the existence of an additional protective cell membrane in the former, which often results in Gram-negative bacteria being less susceptible to conventional, topical antibacterial actives.
  • There exist several contemporary compositions and methods for reducing and/or eliminating the formation of bacteria and/or viruses. For example, it is well known that the washing of hard surfaces, food (e.g. fruit or vegetables) and skin, especially the hands, with antimicrobial or non-medicated soap, is effective against viruses and bacteria. Actually, removal of the viruses and bacteria is due to the surfactancy of the soap and the mechanical action of the wash procedure, rather than the function of an antimicrobial agent. Thus, it is recommended that people wash frequently to reduce the spread of viruses and bacteria. However, many conventional products and methods of sanitization, including washing, fail to address the dilemma of sanitization “on the go”, that is to say, when a consumer is removed from the benefit of running water. Those skilled in the art have attempted to resolve this dilemma via the incorporation of antimicrobial agents into disinfecting lotions, cleansing wipes and the like. Such articles reduce the need for water during or following the application of the subject composition.
  • Other conventional antimicrobial cleansing products include deodorant soaps, hard surface cleaners, and surgical disinfectants. These traditional, rinse-off antimicrobial products have been formulated to provide bacteria removal during washing. A few such products, including antimicrobial soaps, have also been shown to provide a residual effectiveness against Gram-positive bacteria, but provide limited residual effectiveness against Gram-negative bacteria. By “residual effectiveness”, it is meant that the subject antimicrobial controls microbial growth on a substrate by either preventing growth of microbes or engaging in continuous kill of microbes for some period of time following the washing and/or rinsing process. To address the dilemma of limited residual efficacy against Gram-negative bacteria, those skilled in the art have sought to incorporate high levels of alcohol and/or harsh surfactants into contemporary antimicrobial products, which have been shown to cause dryness and irritation to skin tissues.
  • Thus, there remains a substantial need to identify and deploy antimicrobial compositions that may be used by consumers “on the go”; provide immediate and residual kill of microbes with or without washing; and prevent dryness and irritation to skin following application. Despite providing a quasi solution to the dilemma of water availability, those skilled in the art have yet to identify antimicrobial compositions that address the problems associated with dryness and irritation to skin. In fact, attempts to resolve this dilemma have generally resulted in the adoption of aqueous-based antimicrobial formulas incorporating high levels of zwitterionic surfactants that are too weak to provide significant immediate or residual benefits. Others have attempted to address the dilemma of dryness or irritation to skin by incorporating cationic surfactants into antimicrobial compositions, which have been associated with adverse impacts on the environment and human health. Yet others still have attempted to resolve this dilemma via the incorporation of long-chain anionic surfactants into antimicrobial compositions, which are intended to prevent skin tissue penetration. Nevertheless, such surfactants are often associated with poor phase stability in product, incompatibility with commercial antimicrobial agents, and low residual kill performance. Indeed, the identification of a balance between the factors of antimicrobial performance, skin mildness and water availability continues to be a key concern to those of skill in the antimicrobial art.
  • SUMMARY OF THE INVENTION
  • The present invention addresses and resolves all of the problems associated with the employment of conventional antimicrobial compositions and/or products. Indeed, it has been surprisingly discovered that a composition incorporating an organic acid or organic acid mixture, a specific short-chain anionic surfactant having at least one of a large, hydrophilic head group; an unsaturated structure; and/or a branched structure; constitutes a viable advancement and alternative in the realm of antimicrobial formulations. The antimicrobial compositions of the present invention are adapted for direct application to human skin, without causing dryness or irritation. Moreover, the antimicrobial compositions of the present invention are designed for use with or without water, and provide immediate and residual effectiveness in either instance against a variety of viruses and bacteria, including rotavirus, rhinovirus, respiratory syncytial virus (RSV), coronavirus, Gram-positive and Gram-negative bacteria.
  • The specific, anionic surfactant of the present invention presents a particularly novel aspect of the present compositions. Those of skill in the art have generally relied upon the incorporation of longer chain (i.e. C12 to C16) anionic surfactants into antimicrobial compositions. Conventional surfactants, comparable to the acyl components found in the phospholipid matrix of the cell membrane of bacteria and virus, are thought to possess optimum antimicrobial activity with reduced skin tissue penetration. However, conventional anionic surfactants have been associated with low solubility under acidic conditions, poor compatibility with cationic antimicrobial agents, slow dissolution kinetics and limited residual antimicrobial performance.
  • Against the conventional wisdom in the art, the short chain anionic surfactants of the present invention comprise at least one of the following characteristics: a large, hydrophilic head group; an unsaturated structure; and/or a branched structure. Indeed, the surfactants of the present invention have traditionally been regarded as unsuitable for incorporation into an antimicrobial composition, based on the belief that such surfactants possess relatively low surface activity. Contrary to the traditional wisdom, it has been surprisingly discovered that the surfactants of the present invention deliver enhanced antimicrobial efficacy against rotavirus, rhinovirus, respiratory syncytial virus (RSV), coronavirus, Gram-negative bacteria and Gram-positive bacteria. More importantly, the large head group, unsaturated structure and/or branched structure of the present surfactants reduces or limits their tendency to penetrate skin tissue, while maximizing the immediate and residual effectiveness of the antimicrobial compositions in which they are incorporated. Further, the anionic surfactants of the present invention exhibit stability in an aqueous product at a low pH, are compatible with cationic antimicrobial agents and convey strong residual antimicrobial activity when the substrate on which they are applied is later inoculated with virus or bacteria.
  • Thus, in accordance with a first aspect of the present invention, antimicrobial compositions, comprising an organic acid or organic acid mixture, a specific, short-chain anionic surfactant mixture are disclosed. Against the conventional wisdom in the art, suitable anionic surfactants for use in the context of the present invention comprise a chain length of from about C4 to C12 and at least one of the following characteristics: a large, hydrophilic head group; an unsaturated structure; and/or a branched structure. In yet another aspect of the present invention, the antimicrobial compositions disclosed herein optionally further comprise a calcium ion scavenger and/or an anti-foam agent. The compositions of the present invention are adapted to provide immediate and residual kill of numerous bacteria and viruses, with or without the use of water and without causing dryness or irritation to skin.
  • In accordance with a second aspect of the present invention, products incorporating the antimicrobial compositions of the present invention are disclosed. Such products may take an assortment of shapes and forms depending on the precise application for which deployment of the product is desired and the needs and/or abilities of the formulator. In any instance, the products of the present invention are effective in eradicating numerous bacteria and viruses, both immediately and residually and are adapted to prevent dryness and/or irritation to mammalian skin tissue.
  • In accordance with a third aspect of the present invention, methods of using the antimicrobial compositions and products of the present invention are disclosed. The methods of the present invention are adapted to achieve immediate and/or residual kill of a variety of viruses and bacteria, without irritating the skin and with or without the use of water.
  • These and other objects, features, and advantages will become apparent to those of ordinary skill in the art from a reading of the following detailed description and the appended claims. All percentages, ratios and proportions herein are by weight, unless otherwise specified. All temperatures are in degrees Celsius (° C.) unless otherwise specified. All documents cited are in relevant part, incorporated herein by reference.
  • DETAILED DESCRIPTION OF THE INVENTION Antimicrobial Compositions
  • In accordance with a first aspect of the present invention, antimicrobial compositions, adapted for immediate and residual efficacy against a variety of bacteria and viruses, are provided. The compositions of the present invention comprise an organic acid or organic acid mixture; an anionic surfactant having a chain length of from about C4 to about C12 and at least one of the following characteristics: an unsaturated structure, a branched structure; and/or a hydrophilic head group having a total head group size (defined, infra) of between about 4 to about 15 Angstroms. In another aspect of the present invention, the antimicrobial compositions disclosed herein optionally further comprise a calcium ion scavenger and/or anti-foam agent. The compositions of the present invention are characterized by a pH of between about 2.0 to about 4.5, depending on the specific constituents of the present antimicrobial compositions and the application for which their use is intended.
  • Organic Acid
  • Indeed, in one aspect of the present invention, the antimicrobial compositions disclosed herein comprise an amount of an organic acid or organic acid mixture. Organic acids, for purposes of the present disclosure, are defined as proton-donating agents that remain at least partially undisassociated in a concentrated composition and remain so when the compositions are diluted during washing and rinsing. Without wishing to be bound by theory, the organic acids of the present invention serve to protonate the carboxylate functionalities on the phospho lipid membrane of bacteria and virus and reduce the tendency of the membrane to electronically repel anionic surfactants, thereby facilitating proper interaction between the present, anionic surfactants and the membrane. Moreover, the organic acids disclosed herein facilitate the creation of a low pH buffer on the surface of a substrate, thereby prolonging the residual antimicrobial activity of the compositions and products in which they are incorporated.
  • Preferably, the present organic acids are added directly to the compositions of the present invention in acidic form or are formed by adding the conjugate base of the desired acid and an amount of a separate acid sufficient to form the undisassociated acid from the base. The antimicrobial compositions of the present invention comprise from about 0.2% to about 70%, preferably about 0.5% to about 40%, more preferably from about 1.0% to about 30%, based on the total weight of the antimicrobial composition, of an organic acid or organic acid mixture.
  • Suitable organic acids of the present invention include, but certainly are not limited to: pyroglutamic acid, adipic acid, gluconic acid, glyconolactone acid, glutamic acid, glycolic acid, glutaric acid, tartaric acid, ascorbic acid, benzoic acid, salicylic acid, citric acid, malic acid, succinic acid, lactic acid, carboxymethylcellulose and mixtures thereof. In another aspect of the present invention, suitable organic acids for incorporation into the present compositions are characterized by a pKa of greater than about 3.0. Without wishing to be bound by theory, the pKa selection limitation of the present organic acids serves the fundamental goal of ensuring that at least 50% of the organic acids incorporated into the present compositions remain undisassociated at the desired pH of from about 2.0 to about 4.5 (discussed, infra).
  • Optional Calcium Ion Scavenger
  • In another aspect of the present invention, the compositions disclosed herein comprise a calcium ion scavenger. Without wishing to be bound by theory, the calcium ion scavengers of the present invention, too, facilitate the disruption of the cell membrane of bacteria and viruses by the present, anionic surfactants via capture of the calcium ions of the phospholipid cell membrane. Without wishing to be bound by theory, said calcium ions are believed to exist within and around the cell membrane, thereby often preventing the penetration of conventional surfactants. The present, calcium ion scavengers are a particularly preferred ingredient of the present antimicrobial compositions when the targeted microbial is rotavirus. Suitable calcium ion scavengers of the present invention, include, but are not limited to: citric acid, malic acid, succinic acid, polyacrylic acid, copolymers of acrylic acid and maleic acid, oxydisuccinic acid, nitrilotriacetic acid, iminodisuccinic acid, tartrate disuccinic acid, tartrate monosuccinic acid, ethylenediaminetetraacetic acid, pyrophosphoric acid and mixtures thereof. In yet another aspect of the present invention, the calcium ion scavengers of the present invention are characterized by a pKa of lower than about 3.0. Moreover, in another aspect of the present invention, suitable calcium ion scavengers are characterized by a calcium ion binding constant (log P) of greater than about 3.0 at a pH of about 3.
  • Anionic Surfactant
  • The anionic surfactants of the present invention constitute a particularly novel and unobvious aspect of the present invention. Indeed, it has been surprisingly discovered that, contrary to the conventional wisdom in the art, anionic surfactants having a chain length of from about C4 to about C12 and at least one characteristic selected from: a large hydrophilic head group; an unsaturated structure; and/or a branched structure; provide enhanced performance benefits, while minimizing dryness and/or irritation to mammalian skin tissue. The short chain anionic surfactants of the present invention exhibit phase stability in formulation, compatibility with other antimicrobial agents and residual efficacy of the antimicrobial compositions in which they are incorporated. Without wishing to be bound by theory, it is believed that the interaction of short chain anionic surfactant with the phospholipid cell membrane of bacteria and virus, facilitated by the protonation of carboxylate functionalities at the surface of the membrane, disrupts the membrane and denatures cellular proteins, thereby providing rapid microbiocidal activity.
  • The antimicrobial compositions of the present invention comprise from about 0.1% to about 40%, preferably from about 0.2% to about 30%, more preferably from about 0.3% to about 20% of an anionic surfactant mixture. In another aspect of the present invention, the short-chain anionic surfactants disclosed herein are incorporated into the present, antimicrobial compositions at a level of greater than about 25%. In another aspect of the present invention, the anionic surfactants useful for incorporation into the present antimicrobial compositions comprise a relatively short carbon chain, preferably between about C4 to about C12, more preferably between about C6 to about C11, most preferably between about C6 to about C10. It should be noted, however, that, due to the fact that some surfactants suitable for incorporation into the present antimicrobial compositions are commercially available in mixed chain lengths, the average chain length of the resultant anionic surfactant mixture may differ from the above-described ranges.
  • To reiterate, those of skill in the art have generally avoided the-incorporation of so-called “short-chain” anionic surfactants into antimicrobial compositions. This trend is believed to be due in part to the conventional wisdom in the art that short-chain anionic surfactants are characterized by decreased interfacial activity and decreased interaction with the phospholipid membrane of bacteria and virus, and thus, provide poor microbiocidal activity. Accordingly, those of skill in the art have generally relied upon the employment of anionic surfactants with chain lengths of from C12 to C16 in antimicrobial compositions. The chain lengths of such surfactants are comparable to those of the acyl components in the phospholipid membrane of bacteria and virus, and thus, are thought to provide optimum microbiocidal activity. Moreover, longer chain surfactants have conventionally been thought to be less capable of skin penetration, and thus, less likely to cause dryness and irritation to skin. Nevertheless, conventional, longer chain anionic surfactants often exhibit poor phase stability in an acidic product matrix, incompatibility with cationic antimicrobial agents and decreased residual antimicrobial activity. Conversely, the shorter chain anionic surfactants of the present invention exhibit surprisingly high immediate microbiocidal activity, phase stability in broad concentration ranges of acidic aqueous matrices and compatibility with cationic antimicrobial agents. Importantly, the anionic surfactants of the present invention prevent dryness or irritation to skin and demonstrate strong residual microbiocidal activity on a target substrate when the substrate is later inoculated with bacteria or virus.
  • In another aspect of the present invention, the short chain anionic surfactants disclosed herein possess an unsaturated structure and/or a branched, hydrophobic group with a total carbon content ranging from about C4 to about C12, preferably from about C6 to about C11 and more preferably from about C6 to In yet another aspect of the present invention, the short-chain anionic surfactants disclosed herein comprise a hydrophilic head group with a total head group size of less than about 15 Angstroms, preferably less than about 10 Angstroms, more preferably between about 4 to about 7 Angstroms. By “total head group size,” it is meant the accumulated size of every substituent on the hydrophilic head group of the present anionic surfactants. That is to say, the present anionic surfactants may comprise more than one substituent on their subject hydrophilic head groups, for a combined, total hydrophilic head group size falling within the above-listed, ranges. Without wishing to be bound by theory, it is believed that the unsaturated structure and/or branched structure and/or large hydrophilic head group of the present, anionic surfactants increases their water solubility, increases their compatibility with cationic agents, increases steric hindrance to their disruption of the stratum conium layer of skin and maintains their substantivity to the phospholipid membrane of bacteria and viruses.
  • The “hydrophilic head group” is defined as the hydrophilic portion (which may contain both non-hydrocarbon and hydrocarbon units) of the anionic surfactant, measured from the first polar atom to the end of the hydrophilic segment that links to the hydrophobic body. For example, the hydrophilic head group of alkyl glyceryl sulfonate R—O—CH2CH(OH)CH2—SO3Na is —O—CH2CH(OH)CH2—SO3Na. The hydrophilic head group size is estimated from the Van der Waals radius of the atoms and the configuration of the surfactant molecule. Suitable hydrophilic head groups of the present invention with a size of less than about 10 Angstroms include, but are not limited to: glyceryl ether sulfonates and, for compositions having a pH of greater than 3.5, isethionates, sulfosuccinates, amidosulfonates and ethoxylated sulfonates.
  • In yet another aspect of the present invention, the head group of the anionic surfactant is characterized by substitution of one or more substituents. By “substituents” it is meant any hydrophilic segment that is bonded to the head group, defined hereinbefore, of the present anionic surfactants. Without wishing to be bound by theory, it is believed that such increased substitution on the head group of the present anionic surfactants further increases the size and hydrophilicity of the head group. Suitable hydrophilic head groups of the present invention with multiple substituents include, but are not limited to, alpha sulfo fatty acid, and if the pH of the present antimicrobial compositions is greater than 3.5, monoester of sulfosuccinic acid. To reiterate, the head group size of the present anionic surfactants is defined on the basis of Angstroms, as discussed supra. Thus, although the hydrophilic head group of the present anionic surfactants may comprise more than one substituent, the total hydrophilic head group size should not exceed the preferred size ranges, set forth hereinbefore, in Angstroms.
  • Accordingly, suitable anionic surfactants of the present invention, meeting all of the criteria discussed hereinbefore include, but certainly are not limited to: linear or branched alkyl glyceryl sulfonate, alkyl alpha sulfo fatty acid, alpha olefin sulfonate, branched alkyl sulfonate, branched alkyl benzene sulfonate, branched alkyl phosphonate and if the pH of the antimicrobial composition is greater than about 3.5, secondary alkyl sulfate, alkyl isethionate, monoester of alkyl sulfosuccinic acid, alkyl aminosulfonate, alkyl ethoxylated sulfonate, and combinations thereof. The aforementioned list is only intended to serve as a guide to the formulator of the present, antimicrobial compositions. Additional anionic surfactants having a chain length of from about C4 to about C12 and comprising at least one of the following characteristics are suitable for use herein: an unsaturated structure; a branched structure and/or a hydrophilic head group size as described hereinbefore. Selection of the appropriate anionic surfactant for use in the antimicrobial compositions of the present invention will depend upon the needs and/or abilities of the formulator. In another aspect of the present invention, other surfactants, many commercially available, are incorporated into the antimicrobial compositions of the present invention. Said surfactants, although depending on the precise form of the desired antimicrobial composition, include, but certainly are not limited to: paraffin sulfonate, hydrolyzed methyl ester sulfonate, alkyl sulfosuccinate, alkyl glyceryl sulfonate, alpha olefin sulfonate, alkyl isethionate, secondary alkyl sulfate, branched alkyl benzene sulfonate, alkyl sulfate and combinations thereof.
  • It should be noted and underscored that selection of the appropriate anionic surfactant for use in the context of the antimicrobial compositions of the present invention will depend upon several factors, including, but certainly not limited to: the nature of the substrate for which use of the antimicrobial compositions disclosed herein is desired and the needs and/or abilities of the formulator and/or practitioner of the present compositions. For instances in which the mildness of the present antimicrobial compositions on skin is not an issue, short chain anionic surfactants having a hydrophilic head group size of less than about than 4 Angstroms and/or a linear structure may be suitable for use in the context of the present invention. Indeed, for instances in which mildness of the present compositions on skin is not a fundamental concern, suitable anionic surfactants for use in the context of the present invention include, but certainly are not limited to: sulfonates and sulfates having a linear chain with a chain length of from about C4 to about C12, preferably having a chain length of from about C6 to about C12, more preferably having a chain length of from about C8 to about C12.
  • Anti-Foam Agent
  • In another aspect of the present invention, the antimicrobial compositions disclosed herein comprise an anti-foam or suds suppression agent. Incorporation of said agents is particularly desired for applications in which the present antimicrobial compositions comprise high sudsing, short chain anionic surfactants such as alkyl glyceryl sulfonate and/or a level of anionic surfactant of greater than about 1 weight percent. Incorporation of an anti-foam agent or suds suppression system is further advantageous in compositions for which low foaming is desired, particularly when such foaming has the affect of decreasing the conveyance of antimicrobial dosage. In one aspect of the present invention, the antimicrobial compositions disclosed herein comprise an anti-foam or suds suppression agent, present at a level of from about 0.0001% to about 15%, preferably from about 0.001% to about 10%, most preferably from about 0.005% to about 5% by weight of the antimicrobial composition. In another aspect of the present invention, the anti-foam agent is present in an amount of at least 1 ppm by weight of the total composition. Without wishing to be bound by theory, it is believed that incorporation of an anti-foam agent or suds suppression system serves the fundamental goal of controlling the suds profile of the present compositions during production and ensuring the delivery of an optimum dosage of the present antimicrobials during employment. Indeed, suitable suds suppressing systems for use herein may comprise essentially any known antifoam compound that exhibits stability at a pH of about 2.0 to about 4.5, including, but not limited to, those selected from the group consisting of: silicone antifoam compounds, silicone emulsions, 2-alkyl and alkanol antifoam compounds, mineral oil emulsions, hydrocarbon oil emulsions, polyalkylene emulsions and combinations thereof.
  • Silicone suds suppressor technologies and other anti-foam agents useful herein are extensively documented in “Defoaming, Theory and Industrial Applications”, Ed., P. R. Garrett, Marcel Dekker, N.Y., 1973, ISBN 0-8247-8770-6, incorporated herein by reference. See especially the chapter “Surfactant Antifoams” (Blease et al). See also U.S. Pat. Nos. 3,933,672 and 4,136,045, both incorporated herein by reference. Highly preferred silicone suds suppressors are the compounded types known for use in antimicrobial compositions, including, for example, polydimethylsiloxanes having trimethylsilyl or alternate endblocking units. Such compounds may be compounded with silica and/or with surface-active nonsilicon components, as illustrated by a suds suppressor comprising 12% silicone/silica, 18% stearyl alcohol and 70% starch. A suitable, commercial source of the silicone active compounds is Dow Corning Corp.
  • Optional Nonionic Agent
  • In accordance with another aspect of the present invention, the antimicrobial compositions disclosed herein further comprise a nonionic agent. In one aspect of the present invention, suitable nonionic agents for use in the present compositions are selected from the group consisting of: alkyl polyols, alkyl alcohols, phenols, chloro phenols, polyphenols and mixtures thereof. Without wishing to be bound by theory, it is believed that the optional nonionic agent of the present invention serves many roles, including, but certainly not limited to, increasing the antibacterial efficacy, in both immediate and residual kill, of the organic acid and short chain anionic surfactant system of the present invention. Some alkyl polyols, such as 1-(2-ethylhexyl)glycerol ether, have conventionally been thought to inhibit bacteria, and thus, have traditionally been employed as preservatives in commercial cosmetic products. Indeed, it has surprisingly been discovered that use of alkyl polyols and alkyl alcohols in the present compositions has the affect of increasing the immediate and residual activity of the present compositions. When present, the nonionic agents of the present invention are incorporated into the present antimicrobial compositions in an amount of from about 0.1% to about 10%, preferably from about 0.1% to about 5%, more preferably from about 0.1% to about 3%, by weight of the total, antimicrobial composition. In another aspect of the present invention, when the antimicrobial compositions of the present invention comprise a nonionic agent, said agent comprises a carbon chain length of from about C3 to about C12. Suitable nonionic agents for incorporation into the antimicrobial compositions of the present invention include, but certainly are not limited to: 1-(2-ethylhexyl)glycerol ether, octyl glycerol ether, 2-(2-ethylhexylxoxy)propanol, octyloxy propanol, 1-(2-ethylhexyloxy)ethanol, octyloxy ethanol, 1,2 hexylenediol, 1,2-cyclohexanedimethanol, isopropyl glycerol ether, 4-chloro-3-xylenol and combinations thereof. In another aspect of the present invention, the nonionic agent is branched, unsaturated or linear. In yet another aspect of the present invention, the nonionic agent is substituted with compounds selected from the group consisting of: alcohols, polyols, phenols, chloro phenols, polyphenols and combinations thereof.
  • Optional Adjunct Ingredients
  • In another aspect of the present invention, the compositions disclosed herein will comprise one or more adjunct ingredients. Said ingredients may be employed to increase the mildness of the desired composition, increase immediate and/or residual efficacy of the subject compositions, improve the wetting characteristics of the subject compositions upon application to a target substrate, operate as solvents for diluted compositions, and/or serve to modify the aesthetic characteristics of the composition. In one aspect of the present invention, the compositions disclosed herein comprise from about 0% to about 70%, preferably from about 0% to about 62%, more preferably from about 0% to about 10%, of an alcohol solvent. Suitable alcohol solvents of the present invention include, but are not limited to, ethanol, propanol, butanol, propylene glycol, diethylene glycol, dipropylene glycol and mixtures thereof.
  • In another aspect of the present invention, the compositions disclosed herein comprise from about 0% to about 10%, preferably from about 0% to about 5%, more preferably from about 0% to about 1%, of a cationic antimicrobial agent. Depending on the region in which the formulator chooses to practice the present compositions, the inclusion of one or more cationic surfactants may be necessary for the procurement of regulatory approval. Suitable cationic antimicrobial agents for use in the compositions of the present invention, include, but certainly are not limited to, benzalkonium chloride, benzethonium chloride, triclocarban, tricolsan, chlorhexidine and mixtures thereof.
  • In yet another aspect of the present invention, the compositions disclosed herein comprise from about 0% to about 5%, preferably from about 0% to about 2%, of a heavy metal salt selected from the group consisting of: silver, zinc, copper and mixtures thereof. Incorporation of said heavy metal salt serves to increase the antimicrobial activity and the viscosity of the present, antimicrobial compositions. Moreover, the other ingredients of the present compositions have exhibited compatibility with the heavy metal salts disclosed herein. In another aspect of the present invention, the compositions disclosed herein comprise from about 0% to about 20%, preferably from about 0% to about 5%, of a skin emollient or moisturizer. Such ingredients serve the fundamental purpose of increasing the mildness (discussed infra) of the present antimicrobial compositions and are particularly desired when incorporating the present antimicrobial compositions into a skin care product (discussed infra).
  • In yet another aspect of the present invention, one or more adjunct ingredients are incorporated into the antimicrobial compositions disclosed herein, to facilitate formulation of the desired composition. Those of skill in the art will readily appreciate that the inclusion of additional adjunct ingredients is often necessary to formulate certain ingredients included in the present compositions and in antimicrobial compositions generally. Indeed, it has been discovered, and documented via the present disclosure, that the formulation of certain perfumes and/or skin emollients in antimicrobial compositions requires the use of alkyl polyether-type emulsifiers. It has been learned that the use of said alkyl polyether-type emulsifiers is necessary to achieve physical stability of the resultant antimicrobial product when attempting to formulate certain perfumes and/or skin emollients. Although other types of emulsifiers are commercially available and often used in the context of formulation of antimicrobial-type compositions, the inventors of the subject matter disclosed herein have discovered that the use of emulsifiers other than those of the alkyl polyether-type, results in a chemically instable, yet efficacious, end product.
  • Thus, in yet another aspect of the present invention, the antimicrobial compositions disclosed herein comprise from about 0.05% to about 5%, preferably from about 0.1% to about 1%, more preferably from about 0.2% to about 0.5% of an alkyl polyether-type emulsifier. Non-limiting examples of alkyl polyether-type emulsifiers suitable for incorporation into the antimicrobial compositions disclosed herein include: isoceteth-20 (CAS No. 69364-63-2) and ceteth-20 (CAS No. 9004-95-9). In yet still another aspect of the present invention, use of the alkyl polyether-type emulsifiers disclosed herein are provided for use in the context of formulation of any antimicrobial composition comprising one or more otherwise physically instable adjunct ingredients, and not specifically limited to the antimicrobial compositions disclosed herein. In this respect, examples of said otherwise physically instable adjunct ingredients, include, but certainly are not limited to: perfumes, skin emollients, other nonionic agents and mixtures thereof.
  • In yet still another aspect of the present invention, other ingredients are included into the antimicrobial compositions to achieve physical stability for perfumes, skin emollients and other adjunct incorporated therein that otherwise exhibit physical instability absent the use of such adjuncts. Accordingly, the present invention further seeks to encompass the use of sulfonate anionic surfactant having a chain length of C12 to C18 are suitable for use in the context of the antimicrobial compositions disclosed herein, and are particularly preferred when the formulator of the present compositions seeks to incorporate certain adjuncts such as perfumes, skin emollients and combinations thereof. Thus, in accordance with this aspect of the present invention, the antimicrobial compositions disclosed herein comprise from about 0 to about 5%, preferably from about 0.1% to about 2%, more preferably from about 0.2% to about 1%. Suitable sulfonate anionic surfactants for use in the context of the present invention include, but certainly are not limited to: C14-18 paraffin sulfonate and C14-18 alkyl alpha olefin sulfonate. To reiterate, the incorporation of sulfonate anionic surfactants is particularly preferred in the context of the present invention when the formulator of the present compositions seeks to include perfumes, skin emollients and combinations thereof.
  • pH of Antimicrobial Compositions
  • It is fundamental to achieving the benefits of the present invention that the undisassociated acid from the organic acids disclosed hereinbefore remain on the skin in the protonated form. Thus, the pH of the antimicrobial compositions of the present invention must be adjusted to a sufficiently low level in order to either form or deposit substantially undisassociated acids onto the substrate for which treatment is desired. By “substantially undisassociated,” it is meant that, upon application of the present compositions onto a target substrate, such as mammalian skin, about 30%, preferably 50%, more preferably 70%, of the organic acids incorporated in said compositions remain undisassociated following the elapse of about 30 minutes from application. The pH of the present compositions should be adjusted and preferably buffered to achieve the desired range. In another aspect of the present invention, the antimicrobial compositions disclosed herein are characterized by a pH of from about 2.0 to about 4.5, preferably from about 2.5 to about 4.0. Indeed, the pH of the antimicrobial compositions of the present invention will depend upon the precise ingredients incorporated into the subject compositions. Nevertheless, the pH of the present compositions is generally, and preferably, above about 2.0, as compositions characterized by a pH below 2.0 are typically required to be identified as toxic or hazardous materials.
  • Mildness of Antimicrobial Compositions
  • Topically applied products, including rinse-off cleansers and leave-on sanitizers, have conventionally possessed the tendency to irritate or dry mammalian skin. The compositions of the present invention, however, provide immediate and residual kill of bacteria and viruses, while possessing the fundamental characteristic of mildness. By “mildness” it is meant the degree to which a composition prevents dryness or irritation to skin. Factors that influence the mildness of a topically applied antimicrobial product include, but are not limited to, duration of exposure to the product, the frequency of use of the product and the degree to which the skin is occluded following exposure to the product.
  • Irritation is observed by several methods, including but not limited to, visual and instrumental assessment of the erythema for redness and of the skin for edema following application of an antimicrobial product. Irritation may be measured by determining the transepidermal water loss (TEWL) of skin before and after exposure to an antimicrobial product, using, for example, a TEWL meter. Indeed, products that cause irritation may eventually compromise the natural barrier function of mammalian skin—resulting in increased water loss through the epidermis. Dryness is observed by several methods including, but not limited to, visual and instrumental assessment of the level and severity of dry skin flakes following exposure to an antimicrobial product. Dryness may be measured by instruments that examine the water content of the skin. One such instrument, a corneometer, measures the water content of skin via capacitance.
  • The present invention, despite its enormous cleaning and antimicrobial characteristics, is adapted to ensure increased mildness to mammalian skin upon application, particularly when compared to conventional cleansers such as bar or liquid soap and leave-on sanitizers. Indeed, the efficacy and mildness of the compositions of the present invention has been examined and illustrated under a variety of use conditions and methods. Namely, during a 10-day clinical forearm study, subjects applying the compositions of the present invention experienced significantly less skin irritation and dryness than subjects engaging in the same number of washes per day with soap and water and subjects applying conventional alcohol-based hand sanitizers. The results of the aforementioned study were measured using both visual and instrumental methods. The 10-day clinical forearm study is intended to mirror the hand washing and/or sanitizer use frequency typically recommended for proper hygiene. In another study, the leave-on application of the present compositions was applied 4 times daily, in addition to normal hand washing, and resulted in no measurable skin irritation or dryness.
  • Products Incorporating Antimicrobial Compositions
  • The present invention further relates to products that comprise the antimicrobial compositions of the present invention, as well as combinations of such products. Indeed, the combined and systematic use of products containing the antimicrobial compositions of the present invention serves to eradicate viruses (e.g. rhinovirus, rotavirus, respiratory synμcytial virus (RSV), coronavirus) and bacteria (e.g. Gram-positive and Gram-negative) for a longer period of time and prevent their spread.
  • Personal Care Products
  • Thus, in accordance with a first aspect of the present invention, personal care products comprising the antimicrobial compositions of the present invention are disclosed. Suitable personal care products comprising the antimicrobial composition of the present invention, include, but are not limited to: hand soaps, hand sanitizers, body washes, mouth washes, toothpastes, shower gels, shampoos, body lotions, deodorants, nasal sprays, foot care, vaginal care and/or wash, pet care and combinations thereof. In yet another aspect of the present invention, the personal care products disclosed herein take the form of a wipe product, particularly suitable for wiping or drying the face or hands. In such instance, the antimicrobial compositions of the present invention are preferably embedded or impregnated into said wipe product. In yet still another aspect of the present invention, the personal care product disclosed herein takes the form of a tissue or towel, also suitable for wiping or drying the face or hands. In another aspect of the present invention, the personal care product takes the form of a feminine napkin and/or a diaper. In another aspect of the present invention, the personal care product takes the form of a first aid antiseptic for irritated, injured, or acne-affected skin and/or for pre or post surgical use.
  • Household Care Products
  • In another aspect of the present invention, the antimicrobial compositions of the present invention are incorporated into one or more household care products. Indeed, suitable household care products for purposes of the present invention include, but are not limited to: hard surface cleaners, deodorizers, fabric care compositions, fabric cleaning compositions, manual dish detergents, automatic dish detergents, floor care compositions, kitchen cleaners or disinfectants, bathroom cleaners or disinfectants and combinations thereof. In another aspect of the present invention, the household care product takes the form of a wipe or towel, suitable for household cleaning and/or care. In yet another aspect of the present invention, the household care products disclosed herein comprise certain adjunct ingredients. Said adjuncts include, but certainly are not limited to: detersive enzymes, builders, bleaching agents, bleach activators, transitional metal bleach catalysts, oxygen transfer agents and precursors, soil release agents, clay soil removal and/or anti-redeposition agents, polymeric dispersing agents, brightener, polymeric dye transfer inhibiting agents, chelating agents, anti-foam agents, alkoxylated polycarboxylates, fabric softeners, perfumes, carriers, hydrotropes, processing aids, dyes or pigments, solvents for liquid formulations, solid fillers, detersive surfactants and combinations thereof.
  • Skin Care Products
  • In another preferred aspect of the present invention, the antimicrobial compositions of the present invention are incorporated into a skin care product. In one aspect of the present invention, the skin care product incorporates a dermatologically acceptable carrier to facilitate safe transfer of the antimicrobial composition of the present invention to the desired area of the skin. In another aspect of the present invention, the skin care product of the present invention comprises certain adjunct ingredients. Said adjuncts include, but certainly are not limited to: antimicrobial and antifungal actives, surfactants, desquamation actives, anti-acne actives, anti-wrinkle actives, anti-atrophy actives, anti-oxidants, radical scavengers, chelators, flavonoids, anti-inflammatory agents, anti-cellulite agents, topical anesthetics, tanning actives, sunscreen actives, conditioning agents, thickening agents, detackifying agents, odor control agents, skin sensates, antiperspirants and mixtures thereof. Indeed, a complete description and examples of each of the aforementioned adjunct ingredients is set forth in U.S. Pat. No. 6,294,186, assigned to The Procter and Gamble Company, Cincinnati, Ohio and incorporated herein by reference.
  • Articles of Manufacture & Kits
  • Moreover, articles of manufacture comprising the antimicrobial compositions of the present invention and/or one or more of the aforementioned products, are intended for personal care, skin care and household care applications. The article of manufacture of the present invention encompasses one or more products as described hereinbefore that may be packaged in a container or dispenser with a set of instructions for the consumer. The article of manufacture of the present invention typically comprises (a) container or dispenser, (b) product and (c) set of instructions to apply said product to an appropriate substrate to achieve immediate and residual antimicrobial activity. Containers and/or dispensers suitable for the article of manufacture of the present invention include, but are not limited to: PET bottles and tubs, flow-wrap pouches, foaming dispensers, spray dispensers and combinations thereof. To reiterate, the article of manufacture of the present invention further comprises a set of instructions in association with the container. By “in association with,” it is meant that the instructions are either directly printed on the container or dispenser itself or presented in a different fashion including, but not limited to: a brochure, print advertisement, electronic advertisement and/or verbal communication, so as to communicate the set of the instructions to a consumer of the article of manufacture.
  • The set of instructions typically comprise the instructions relating to the use of the product to apply the antimicrobial composition of the present invention onto a suitable substrate for which treatment is sought. The set of instructions may further comprise the instruction to allow the antimicrobial composition of the present invention to remain on the treated substrate, without rinsing or otherwise removing the antimicrobial composition from the treated substrate. Nevertheless, the precise instructions included with the article of manufacture of the present invention will depend on the precise ingredients of the subject antimicrobial composition and the product for which the inclusion of instructions is desired and the substrate onto which application of the product is intended. In another aspect of the present invention, the instructions included in the present articles of manufacture coincide with the methods set forth in the “Methods of Use” section of the present disclosure.
  • Methods of Use
  • The antimicrobial compositions and products of the present invention are suitable for a variety of uses. Indeed, suitable uses of the present compositions include, but certainly are not limited to, the eradication of viruses and/or bacteria; the provision of residual anti-viral efficacy; the provision of residual antibacterial efficacy; the prevention and/or treatment of a common cold or associated respiratory disease in a mammal; the prevention and/or treatment of a diarrhea disease in a mammal; the prevention and/or treatment of bacteria-related diseases in mammals resulting from contact with a bacteria-infected surface; the sanitization of hard surfaces; the improvement of the overall health of a mammal; the reduction of absenteeism; the prevention and/or treatment of dandruff and acne; and combinations thereof. It should be noted that, in the case of preventing or treating a common cold or respiratory disease, treatment with the compositions and products disclosed herein is effective when the cold or respiratory disease is caused by rhinovirus, coronavirus or RSV. It should be noted that, in the case of diarrhea, treatment with the present compositions and/or products is effective when the diarrhea is caused by rotavirus or bacteria.
  • Indeed, in one aspect of the present invention, a method of killing bacteria is provided. Said method comprises the steps of topically applying the composition and/or product of the present invention to an area in need of treatment and, optionally, removing said composition and/or product following application. In another aspect of the present invention, a method of inactivating viruses is disclosed. Said method, too, comprises the steps of topically applying the composition and/or product of the present invention to an area in need of treatment and, optionally, removing said composition and/or product following application. The method of inactivating viruses is useful in treating viruses selected from the group consisting of: rotavirus, rhinovirus and combinations thereof.
  • Indeed, in another aspect of the present invention, a method of providing residual antibacterial and antiviral efficacy is provided. Said method preferably comprises the steps of topically applying the composition and/or product of the present invention to an area in need of treatment and, optionally, removing said composition following application. In yet another aspect of the present invention, a method of preventing and/or treating a respiratory disease or diarrhea in a mammal where the sickness is caused by a rhinovirus, coronavirus, RSV or rotavirus; respectively, is envisioned. Said method comprises the steps of topically applying the composition and/or products of the present invention to an area of the mammal in need of treatment and, optionally, removing said composition and/or product following application. Moreover, the present invention seeks to encompass a method of preventing and/or treating bacteria-related diseases in a mammal that result from said mammal's contact with a bacteria-infected substrate. Said method comprises the steps of topically applying the composition and/or product of the present invention to an area of the mammal that is infected with said bacteria and, optionally, removing said composition and/or product following application.
  • To reiterate, each of the methods of the present invention comprise the step of topically applying a composition or product comprising same to an area or surface in need of treatment. Examples of areas and/or surfaces in need of treatment, against which the compositions of the present invention are effective, include, but are not limited to: one or more hands, a nose, a nasal canal or passage, an article of clothing, a hard surface, irritated, acne-affected, or injured skin, pre or post surgical areas and combinations thereof.
  • The exact amount of antimicrobial composition and/or nature of a product will depend upon the needs and abilities of the formulator and practitioner of the present methods.
  • Nevertheless, when the antimicrobial compositions or products of the present invention are topically applied to keratinous tissue, e.g. adult hands, they are applied in doses of from about 0.1 mL to about 5 mL per use, more preferably 0.5 mL to about 4 mL, most preferably from about 1 mL to about 3 mL. Moreover, the compositions and products of the present invention are topically applied to surfaces in need of treatment from about 2 to about 6 times daily. Once applied, the compositions are rubbed on the treated surfaces for a period of time to ensure coverage, typically at least 5 seconds, preferably at least 10 seconds, more preferably at least 20 seconds and most preferably at least 30 seconds.
  • PREPARATIVE EXAMPLES
  • The antimicrobial compositions and products of the present invention were prepared in accordance with the present disclosure. Table 1 and 2, set forth as follows, summarizes the preparation of sixteen antimicrobial compositions in accordance with the present invention. Example 12 and 16 relate to the preparation of a concentrated version of the antimicrobial compositions of the present invention. The product solution of Examples 1 to 12 in Table 1 changed opacity from clear to hazy over time, due to the slow hydrolysis of hydrogenated castor oil. However, the antimicrobial efficacy of the solutions included therein remained unaffected. Contrarily, Examples 13 to 16 in Table 2 remained stable as clear aqueous solutions with consistent antimicrobial performance after prolonged storage under stressed conditions (e.g. one month at 45 degree C.). Moreover, Tables 3 to 6 summarize the efficacy of a few examples, the preparation of which is summarized in Tables 1 and 2. The following disclosure further includes a discussion of the testing methods and results of the compositions disclosed herein, as well as methods for preparing one or more products in accordance with the present invention.
  • TABLE 1
    COMPOSITIONAL EXAMPLES
    EX EX EX 12
    Component EX 1 EX 2 EX 3 EX 4 EX 5 EX 6 EX 7 EX 8 EX 9 10 11 (Conc)
    Sodium Octyl 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 15
    Glyceryl
    Sulfonate
    Sodium Salt 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
    Pyrrolidone
    Carboxylate
    Gluconic Acid 1.5 1.5 1.5
    Hydrogenated 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 1.0
    Castor Oil
    Perfume 0.05-0.1 0.05-0.1 0.05-0.1 0.05-0.1 0.05-0.1 0.05-0.1 0.05-0.1 0.05-0.1 0.05-0.1 0.05-0.1 0.05-0.1 0.5-0.1
    Citric Acid 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 0.5 5
    anhydrous
    Malic Acid 1.5
    Methyl 1.0 1.0
    Cellulose
    3[(2- 0.5
    Ethyhexyl)
    oxy] 1,2
    Propanediol
    Benzalkonium 0.1
    Chloride
    Propylene 3
    Glycol
    2-Propanol 8
    Aloe Vera 0.1
    Menthol 0.1
    PH adjusted 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0
    by 1N Na OH
  • TABLE 2
    COMPOSITIONS EXAMPLES
    EX EX EX 16
    Component 13 EX 14 15 (Conc)
    Sodium Octyl 0.5 0.5 0.5 10
    Glyceryl
    Sulfonate
    Gluconic Acid 2.0 2.0 2.0 20
    Isoceteth-20 0.35 0.35 2-5
    Propylene Glycol 0.1-0.3 0.25 2-5
    Perfume 0.075-0.125 0.15 1-2
    Methyl Cellulose 1.0
    Polyacrylic Acid (MW 3000-6000) 0.25
    Aloe Vera 0.1 0.2 2
    Menthol 0.05 0.15
    Ethanol 10
    PH adjusted by 1N NaOH 3.0 3.0 3.0 3.0
  • TABLE 3
    EFFICACY OF COMPOSITIONS
    Log reduction Time Kill
    Liquid (1 min):
    Composition Challenge Organism Suspension Test
    EX 7 E. coli ATCC 11229 >4
    EX 7 Corynebacterium striatum >4
    ATCC 6940
    EX 7 Corynebacterium >3
    mucifaciens axillary
    isolate 29
    EX 7 Staphylococcus 3
    epidermidis ATCC 35984
    EX 7 Staphylococcus >4
    epidermidis axillary
    isolate 9
  • TABLE 4
    EFFICACY OF COMPOSITIONS
    E. coli
    Log
    reduction E. coli Rotavirus Rotavirus
    Time Kill E. coil Log Log Log Log
    Liquid (1 min): Reduction Reduction Reduction Reduction
    Com- solution Immediate: Residual Immediate: Residual:
    position & wipe Vitro skin Vitro skin Vitro skin Bio Skin
    EX 1 5 4 4 3
    EX 3 5 5 5 3 3
    EX 4 3 3
    EX 7 4 4
    EX 8 4 5
    EX 9 4 4
    EX 10 3 4
    EX 11 5 3 4 2
  • TABLE 5
    EFFICACY OF COMPOSITIONS
    CHALLENGE ORGANISM EX 13 EX 14
    E. coil 11229:
    Log Reduction Immediate; Bio skin 5 5
    Log Reduction Immediate; Bio skin 5 5
    Rotavirus Strain WA from University
    of Ottawa, Ontrio, Canada:
    Log Reduction Immediate; Bio skin 4 4
    Log Reduction Residual; Bio skin 3 5
    Corona Virus ATCC 229 E:
    Log Reduction Immediate; Bio skin 4
    Log Reduction Residual; Bio skin 4
    Rhinovirus ATCC 16:
    Log Reduction Immediate; Bio skin 4 4
    Log Reduction Residual; Bio skin 3
    RSV ATCC VR-26:
    Log Reduction Immediate; Bio skin 4
  • TABLE 6
    EFFICACY OF WIPE PRODUCTS
    E. coil Log reduction Time Kill
    Wipe Product (5 min): wipe substrate
    EX 1 3
    EX 9 4
  • Compositional Testing Antibacterial Efficacy Assay In Vitro Skin #1013 (IMS)/Bio Skin Black #10 Method: Assay In Vitro Skin/Bio Skin Immediate Efficacy:
  • 10 μL of test bacteria suspension was spread on mammalian skin and allowed to air dry for one minute, then 20 μL of the active solution was spread evenly over the treated skin and the preparation was allowed to rest uncovered for five minutes. The skin substrate was placed into a test tube containing 10 mL of extraction solution (Phosphate buffer with Triton X-100, Lecithin and Tween) and vortex for 30 seconds. A 50 μL aliquot was dispensed (via Spiral Biotech Autoplater) onto Trypticase Soy Agar+1.5% Tween 80 plates and viability was determined after 18 hours of incubation at 37° C. (CUF/ml)
  • Residual Efficacy:
  • 20 μL of the active solution was spread evenly over mammalian skin and allowed to dry for 15 min. 10 μL of test bacteria suspension was spread evenly over the treated skin and the preparation was allowed to rest covered for five minutes. The skin substrate was placed into a test tube containing 10 mL of extraction solution (Phosphate buffer with Triton X-100, Lecithin and Tween) and vortex for 30 seconds. A 50 μL aliquot was dispensed via Spiral Biotech Autoplater onto Trypticase Soy Agar+1.5% Tween 80 plates and viability was determined after 18 hours of incubation at 37° C. (CUF/ml)
  • Method: Solution Assay—Bacterial Time Kill:
  • A 50 μL of test bacteria suspension (TSB) culture with a density of 1.0E+09 CFUs/ml was mixed with 5 ml of the active solution. After one minute time, the inoculated solution was mixed with DE neutralizing broth (ratio 1:10). A 50-4 aliquot was dispensed via Spiral Biotech Autoplater onto a Trypticase Soy Agar plate. Viability was determined after 18 hours of incubation at 37° C. (CUF/ml)
  • Method: Viral Efficacy Assay In Vitro Skin #1013 (IMS)/Bio Skin Black #10 Immediate Efficacy:
  • 10 μL of test virus suspension was spread on the skin substrate and allowed to air dry at room temperature then 25 μL of the active solution was spread evenly over the treated skin and the preparation was allowed to rest for five minutes. Following the exposure period, a sterile 1.5 ml cryovial containing 1.0 ml of elution medium was inverted over the sink substrate surface and extraction was performed. The solution was mixed and serial 10 fold dilution was performed. The dilutions were assayed for the presence of virus in a host system. The virus titer of the stock was determined by the median cell culture infective dose (TCID 50). Cytotoxicity to the host system (active solution) at tested concentrations was also determined. The virus-product mixture was assayed in numerous units of the host system. Median values of log 10 virus inactivation were calculated.
  • Residual Efficacy:
  • 25 μL of the active solution was spread evenly over the skin and allowed to dry for 15 min. 10 μl of the test virus suspension was spread evenly over the treated skin and the preparation remained in contact for five minutes. Following the exposure period, a sterile 1.5 ml cryovial containing 1.0 ml of elution medium was inverted over the sink substrate surface and extraction was performed. The solution was mixed and serial 10 fold dilution was performed. The dilutions were assayed for the presence of virus in a host system. The virus titer of the stock was determined by the median cell culture infective dose (TCID 50). Cytotoxicity to the host system (active solution) at tested concentrations was also determined. The virus-product mixture was assayed in numerous units of the host system. Median values of log 10 virus inactivation were calculated.
  • Method: Microbial Susceptibly Test (MST) for Wet Wipes—Time Kill:
  • A test wipe was inoculated with 1.0 ml of virus suspension to cover one quarter of the folded wipe. 5 minutes after inoculation the treated wipe was placed into a sterile bag containing 100 ml of DE neutralizer medium, the bag was sealed and placed in the Stomacher for 2 minutes. After blending, a 50 μL it aliquot was dispensed (via Spiral Biotech Autoplater) onto Trypticase Soy Agar+1.5% Tween 80 plates and viability was determined after 18 hours of incubation at 37° C. (CUF/ml)
  • Liquid Composition Preparation for Use in Products
  • Blend the liquefied Isoceteth 20 (Example 14-16), Hydrogenated Castor Oil (Example 1-12), Perfume, Menthol (Example 8, 14 and 15), Propylene Glycol (Example 5, 14, 15 and 16) and (2-Ethyhexyl)Glycerol ether (Example 3). Emulsify the pre-mixed blend to a pre-dissolved Sodium Glyceryl sulfonate solution. Add and dissolve Sodium Pyrrolidone Carboxylate (Example 1-9 and 11), Citric Acid (Example 1-10, 10 and 12), Gluconic Acid (Examples 9, 10, 12-16) and Malic Acid (Example 11). Add to mixture, Isopropanol (Example 6), Ethanol (Example 15), Aloe Vera (Example 7 and 14-16). Adjust pH to 3.0 by 1N Sodium Hydroxide solution or 1N Phosphoric Acid. Slowly add Benzalkonium chloride solution (Example 4). Add Methyl Cellulose (5% aqueous solution) during mixing (Example 2 and 15). Adjust pH to 3.0 by 1N Sodium Hydroxide solution or 1N Phosphoric Acid. Add remaining water to make a target product weight. Check final pH.
  • Products Preparation Example 13 Antimicrobial Hand Sanitizer
  • To deliver the benefits of the present invention in a hand sanitizer form, the liquid composition produced in accordance with the previous section may be packaged in a typical PET bottle with a flip-top cap. Liquid is dispensed to the hands in an amount to ensure complete wetting. Employing this method delivers immediate microbial kill and, upon drying, provides prolonged, residual activity.
  • Example 14 Antimicrobial Wipe
  • The lotion produced in accordance with the previous section may be used to produce a wet wipe product for topical cleaning and/or sanitizing of skin and/or hard surfaces. Such a product is made by saturating a paper or cloth substrate with the liquid composition prepared in accordance with the previous section. The level of saturation depends upon the substrate in which incorporation of the antimicrobial composition is desired. A 5″×8″ hand wipe towelette made from 40-60 grams per square meter spun-lace non-woven material may be saturated with about 1-3 grams of liquid composition. The liquid may be applied to the substrate via spraying and/or soaking prior to final packaging. The wipe may be wrapped in single use pouches made from foil or plastic or packed in groups of 10, 40, or more in multiple use tubs.
  • To deliver the benefits of the present invention in this form, the wipe is removed from its package and is rubbed onto the target surface, in a manner that ensures complete wetting of the surface. The wetting practice removes visible dirt and eradicates bacteria and viruses. Upon drying, the surface experiences residual antimicrobial activity for several hours.
  • Example 15 Antimicrobial Drying Towel
  • The lotion produced in accordance with the previous section may be used to produce a dry towel product for topical cleaning and/or sanitizing of skin or hard surfaces. Such a product is made by saturating a paper or cloth substrate with the liquid prepared in accordance with the preceding section. The substrate is then dried to remove all water. The level of saturation depends upon the substrate in which incorporation of the antimicrobial composition is desired. A 5″×8″ towel made from 40-60 grams per square meter spun-lace non-woven material may be saturated with about 1-3 grams of liquid. The liquid may be applied to the substrate via spraying and/or soaking prior to final packaging. The liquid may also be applied in concentrate form using printing techniques employed in the color design of commercial, paper towels. The towel may then be rolled or inserted into boxes.
  • To deliver the benefits of the present invention in this form, the towel is applied to any wet skin or hard surface to dry it. The water activates the antimicrobial properties of the composition within the towel, which is then imparted onto the surface. Employing this method, the towel dries the target surface, removes visible dirt, delivers antimicrobial kill and provides prolonged, residual activity.
  • Example 16 Anti-Inflammatory Efficacy of RID Compositions
  • Indeed, the antimicrobial compositions, methods and products of the present invention have demonstrated surprising anti-inflammatory benefits in the topical treatment of inflammation or dermatitis. In vitro studies of the present invention and its key components have been conducted to assess the efficacy of the claimed compositions in inhibiting the cycloxygenase (COX) 1 and 2 enzymes. Said enzymes are adapted to convert arachidonic acid in cell membranes to prostaglandin, a messenger agent that conveys a signal to the cells to increase and enhance their inflammatory response. The results of the aforementioned in vitro study demonstrate that the present invention can significantly reduce the activity of both COX 1 and 2 enzymes. This is particularly important when considered in light of the fact that the key components of the present invention, namely, the short chain anionic surfactant with a large head group or branched structure, the organic acid, and the optional calcium ion-scavenging agent, demonstrate only limited efficacy upon employment individually. The results of this in vitro study have been documented in the below-listed chart.
  • % of Initial
    Treatment Sample Enzyme Activity
    (at pH 3.0) COX-1 COX-2
    A. 0.5% Octyl Glyceryl Sulfonate 55 95
    B. 0.5% Pyroglutamic Acid 100 92
    C. 1.5% Citric Acid 94 100
    D. A + B + C 43 53
  • All documents cite are, in relevant part, incorporated herein by reference; the citation of any document is not to be construed as an admission that it is prior art with respect to the present invention.
  • While particular embodiments of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.

Claims (35)

We claim:
1. An antimicrobial composition capable of inactivating viruses comprising:
a. from about 0.2% to about 70% of an organic acid, which is pyroglutamic acid or gluconic acid;
b. from about 0.1% to about 40% of an anionic surfactant mixture having a characteristic selected from the group consisting of:
i. a linear alkyl chain having a chain length of from about C4 to about C12 and a total hydrophilic head group size of at least about 4 Angstroms;
ii. an unsaturated alkyl chain having a chain length of from about C4 to about C12;
iii. a branched alkyl chain having a chain length of from about C4 to about C12; and
iv. combinations thereof; and
c. a calcium ion scavenger, which is citric acid, malic acid, succinic acid, or polyacrylic acid;
wherein said composition is characterized by a pH of from about 2.0 to about 4.5; and
wherein said viruses include one of at least rotavirus, coronavirus, respiratory syncytial virus, and combinations thereof.
2. The composition of claim 1, further comprising an anti-foam agent.
3. The composition of claim 1, wherein said anionic surfactant is selected from the group consisting of: alkyl glyceryl sulfonate, branched alkyl glyceryl sulfonate, alpha sulfo fatty acid, alpha olefin sulfonate, branched alkyl sulfonate, branched alkyl benzene sulfonate, secondary alkyl sulfate, mono ester of alkyl sulfosuccinic acid, alkyl isethionate, alkyl amidosulfonate, branched alkyl phosphonate, branched alkyl phosphate and combinations thereof.
4. The composition of claim 1, further wherein said anionic surfactant is substituted with a substituent selected from the group consisting of: sulfonate, sulfate, phosphonate and combinations thereof.
5. The composition of claim 1, wherein said organic acid is pyroglutamic acid.
6. The composition of claim 1, wherein said organic acid is characterized by a pKa of greater than about 3.0.
7. The composition of claim 1, wherein said calcium ion scavenger is citric acid.
8. The composition of claim 1, wherein said calcium ion scavenger is characterized by a pKa of lower than about 3.0.
9. The composition of claim 1 wherein said calcium ion scavenger is characterized by a calcium ion binding constant log P of greater than about 3.0 at a pH 3.
10. The composition of claim 2, wherein said anti-foam agent is selected from the group consisting of silicone emulsion, mineral oil emulsion, hydrocarbon oil emulsion, polyalkylene emulsion and combinations thereof.
11. The composition of claim 2, wherein said anti-foam agent is present in an amount of at least 1 ppm by weight of total composition.
12. The composition of claim 2, wherein said anti-foam agent is characterized by the structure of dimethyl silicone or a hydrocarbon moiety in oil in water emulsion.
13. The composition of claim 1, further comprising a nonionic agent.
14. The composition of claim 13, wherein said nonionic agent comprises a substituent selected from the group consisting of: alcohol, polyol, phenol, chlorophenol, polyphenol and combinations thereof.
15. The composition of claim 13, wherein said nonionic agent is branched, linear, unsaturated and combinations thereof.
16. The composition of claim 13, wherein said nonionic agent comprises a chain length of from about C4 to about C12.
17. The composition of claim 13, wherein said nonionic agent is selected from the group consisting of: 1-(2-ethylhexyl)glycerol ether, octyl glycerol ether, 2-(2-ethylhexylxoxy)propanol, octyloxy-propanol, 1-(2-ethylhexyloxy)ethanol, octyloxy ethanol, 1,2-hexylenediol, 1,2-cyclohexanedimethanol, isopropyl glycerol ether, 4-chloro-3-xylenol and combinations thereof.
18. The composition of claim 13, wherein said nonionic agent is present in an amount of about 0.1% to about 10% by weight of total composition.
19. The composition of claim 1, further comprising an alkyl ethoxylated emulsifier.
20. An antimicrobial product comprising the antimicrobial composition of claim 1.
21. The antimicrobial product according to claim 20, wherein said product is a personal care product.
22. The personal care product according to claim 21, wherein said personal care product is selected from the group consisting of: hand soaps, hand sanitizers, body washes, shower gels, shampoos, body lotions, feminine care products, foot care products, deodorants, pet care products and combinations thereof.
23. The antimicrobial product according to claim 20, wherein said product is a household care product.
24. The household care product of claim 23, wherein said product is selected from the group consisting of hard surface cleaners, deodorizers, fabric care compositions, fabric cleaning compositions, manual dish detergents, automatic dish detergents, floor waxes, kitchen cleaners, bathroom cleaners and combinations thereof.
25. The antimicrobial product according to claim 20, wherein said product is selected from the group consisting of: a wipe product suitable for personal care use and household cleaning; a toilet tissue; a towel for hand drying, household drying and household cleaning; a facial tissue; a skin care composition; a first aid or surgical antiseptic; a diaper; a feminine napkin; and combinations thereof.
26. The skin care composition according to claim 25, further comprising a dermatologically acceptable carrier for said antimicrobial composition.
27. A method of killing bacteria, said method comprising the steps of topically applying the composition of claim 1 to an area in need of treatment and, optionally, removing said composition following its application.
28. A method of inactivating viruses, said method comprising the steps of topically applying the composition of claim 1 to an area in need of treatment and, optionally, removing said composition following its application.
29. A method of providing residual antibacterial efficacy, said method comprising the steps of topically applying the composition of claim 1 to an area in need of treatment and, optionally, removing said composition following its application.
30. A method of preventing and/or treating a common cold, respiratory disease and diarrhea in a mammal where said diseases are caused by rhinovirus, rotavirus, coronavirus, respiratory syncytial virus and combinations thereof, said method comprising the steps of topically applying the composition of claim 1 to an area of the mammal in need of treatment and, optionally, removing said composition following its applications.
31. A method of preventing and/or treating bacteria-related diseases in a mammal that result from said mammal's contact with a bacteria-infected substrate, said method comprising the steps of topically applying the composition of claim 1 to an ear of the mammal which is infected with said bacteria and, optionally, removing said composition following its application.
32. A method of reducing inflammation, said method comprising the steps of topically applying the composition of claim 1 to an area in need of treatment, and optionally, removing said composition following its application.
33. The method according to claim 32, wherein said inflammation is caused by a source selected from the group consisting of: plants, diaper rash, insect bites, allergic inflammatory reactions and combinations thereof.
34. A method of preventing inflammation, said method comprising the steps of topically applying the composition of claim 1 to an area for which the prevention of inflammation is desired, and optionally, removing said composition following its application.
35. An antimicrobial composition capable of inactivating viruses comprising:
a. from about 0.2% to about 70% of an organic acid, which is pyroglutamic acid or gluconic acid;
b. from about 0.1% to about 40% of an anionic surfactant mixture having a characteristic selected from the group consisting of:
i. a linear alkyl chain having a chain length of from about C4 to about C12 and a total hydrophilic head group size of at least about 4 Angstroms;
ii. an unsaturated alkyl chain having a chain length of from about C4 to about C12;
iii. a branched alkyl chain having a chain length of from about C4 to about C12; and
iv. combinations thereof; and
c. a calcium ion scavenger, which is citric acid, malic acid, succinic acid, or polyacrylic acid;
wherein said composition is characterized by a pH of from about 2.0 to about 4.5;
wherein said viruses include one of at least rotavirus, coronavirus, respiratory syncytial virus, and combinations thereof; and
wherein said compositions provides immediate and residual effectiveness against Gram-positive and Gram-negative bacteria.
US13/914,166 2002-06-21 2013-06-10 Antimicrobial compositions, products and methods employing same Abandoned US20130272986A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/914,166 US20130272986A1 (en) 2002-06-21 2013-06-10 Antimicrobial compositions, products and methods employing same

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/177,445 US20040001797A1 (en) 2002-06-21 2002-06-21 Antimicrobial compositions, products and methods employing same
US10/263,211 US20030235550A1 (en) 2002-06-21 2002-10-02 Antimicrobial compositions, products and methods employing same
US10/600,180 US7569530B1 (en) 2003-06-20 2003-06-20 Antimicrobial compositions, products and methods employing same
US12/410,219 US20090202463A1 (en) 2002-06-21 2009-03-24 Antimicrobial compositions, products and methods employing same
US13/914,166 US20130272986A1 (en) 2002-06-21 2013-06-10 Antimicrobial compositions, products and methods employing same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/410,219 Continuation US20090202463A1 (en) 2002-06-21 2009-03-24 Antimicrobial compositions, products and methods employing same

Publications (1)

Publication Number Publication Date
US20130272986A1 true US20130272986A1 (en) 2013-10-17

Family

ID=40910125

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/600,180 Expired - Fee Related US7569530B1 (en) 2002-06-21 2003-06-20 Antimicrobial compositions, products and methods employing same
US12/410,219 Abandoned US20090202463A1 (en) 2002-06-21 2009-03-24 Antimicrobial compositions, products and methods employing same
US13/914,166 Abandoned US20130272986A1 (en) 2002-06-21 2013-06-10 Antimicrobial compositions, products and methods employing same

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10/600,180 Expired - Fee Related US7569530B1 (en) 2002-06-21 2003-06-20 Antimicrobial compositions, products and methods employing same
US12/410,219 Abandoned US20090202463A1 (en) 2002-06-21 2009-03-24 Antimicrobial compositions, products and methods employing same

Country Status (1)

Country Link
US (3) US7569530B1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017501153A (en) * 2013-12-19 2017-01-12 ユニリーバー・ナームローゼ・ベンノートシヤープ Composition
CN109609590A (en) * 2018-12-21 2019-04-12 扬州倍加洁日化有限公司 A kind of anti-microbial property test method of wet tissue product
US11814514B2 (en) 2017-12-26 2023-11-14 Lotte Chemical Corporation Thermoplastic resin composition and molded product formed therefrom

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050058673A1 (en) 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
JP2008537732A (en) 2005-03-10 2008-09-25 スリーエム イノベイティブ プロパティズ カンパニー Antimicrobial composition comprising an ester of hydroxycarboxylic acid
US10918618B2 (en) 2005-03-10 2021-02-16 3M Innovative Properties Company Methods of reducing microbial contamination
WO2006099325A2 (en) 2005-03-10 2006-09-21 3M Innovative Properties Company Methods of treating ear infections
EP1974715A1 (en) * 2007-03-31 2008-10-01 Zschimmer & Schwarz GmbH & Co KG Chemische Fabriken Liquid composition for impregnating wet wipes
AU2008247605B2 (en) * 2007-05-04 2014-05-15 The Procter & Gamble Company Antimicrobial compositions, products, and methods of use
US20090062391A1 (en) * 2007-08-27 2009-03-05 Kent Christopher New Use of a virucidal ointment in the nares for prevention of transmission and contraction of common colds
US20090263439A1 (en) * 2008-04-18 2009-10-22 The Procter & Gamble Company Antimicrobial Preservative Free Wipe
US7842725B2 (en) 2008-07-24 2010-11-30 Ecolab USA, Inc. Foaming alcohol compositions with selected dimethicone surfactants
US8541356B2 (en) * 2009-11-23 2013-09-24 S.C. Johnson & Son, Inc. Water-activated “green” multi-functional wipe
US9744125B2 (en) * 2010-01-15 2017-08-29 Nuance Health, Llc Use of a virucidal preparation on an area of the face for prevention of transmission or contraction of viral illnesses, or to shorten the duration of, or lessen the severity of viral illnesses
CA2791296A1 (en) * 2010-02-26 2011-09-01 Fresh Express, Inc. Systems and methods for sanitizing produce in an acidic bath
CN102905562A (en) 2010-05-20 2013-01-30 艺康美国股份有限公司 Rheology modified low foaming liquid antimicrobial compositions and methods of use thereof
DE102010063250A1 (en) 2010-12-16 2012-06-21 Henkel Ag & Co. Kgaa Hydrous antiperspirant compositions with improved residue masking
GB2486875A (en) 2010-12-17 2012-07-04 Ronald Alexander Scot Young Acidic anti-pathogenic cleaning composition
WO2012177950A2 (en) * 2011-06-21 2012-12-27 Aqua Technology Systems LLC Modulated ph wipes
BR112014017360A8 (en) * 2012-01-18 2017-07-04 Procter & Gamble acid laundry detergent compositions
DE102012205218A1 (en) 2012-03-30 2013-10-02 Henkel Ag & Co. Kgaa Antiperspirant compositions with cycloaliphatic diols and zirconium salts
US9581255B2 (en) 2012-07-23 2017-02-28 Henning, Inc. Multiple proportion delivery systems and methods
US9393252B2 (en) 2013-03-12 2016-07-19 Ecolab Usa Inc. Aromatic carboxylic acids in combination with aromatic hydroxyamides for inactivating non-enveloped viruses
US9808435B2 (en) 2013-03-12 2017-11-07 Ecolab Usa Inc. Antiviral compositions and methods for inactivating non-enveloped viruses using alkyl 2-hydroxycarboxylic acids
BR112015029254A2 (en) 2013-05-24 2017-07-25 Procter & Gamble low ph detergent composition comprising nonionic surfactants
US9840681B2 (en) 2013-05-24 2017-12-12 The Procter & Gamble Company Concentrated surfactant composition
EP3004310B1 (en) 2013-05-24 2021-07-14 The Procter & Gamble Company Low ph detergent composition
MX350446B (en) 2013-09-30 2017-09-07 Chemlink Laboratories Llc Environmentally preferred antimicrobial compositions.
US20150209272A1 (en) 2014-01-24 2015-07-30 The Procter & Gamble Company Skin care wipes comprising added natural antibacterial agents
US10201481B2 (en) 2014-03-07 2019-02-12 The Procter & Gamble Company Personal care compositions and methods of making same
BR112017001327B1 (en) 2014-07-31 2022-01-25 Kimberly-Clark Worldwide, Inc Non-antimicrobial composition to inhibit the attachment of microbes to a surface, and tissue
MX2017000814A (en) 2014-07-31 2017-05-04 Kimberly Clark Co Anti-adherent alcohol-based composition.
KR102394761B1 (en) 2014-07-31 2022-05-09 킴벌리-클라크 월드와이드, 인크. Anti-adherent composition
MX2017011771A (en) 2015-04-01 2017-12-04 Kimberly Clark Co Fibrous substrate for capture of gram negative bacteria.
CN107920517A (en) 2015-08-18 2018-04-17 高露洁-棕榄公司 Preservative system based on organic acid
BR112018072236A2 (en) 2016-05-26 2019-02-12 Kimberly Clark Co method of inhibiting microbes from attaching to a surface, non-stick composition to prevent microbes from attaching to a surface, and handkerchief to inhibit the attachment of microbes to a surface.
US11571376B2 (en) * 2017-03-28 2023-02-07 Arxada Ag Aqueous antimicrobial composition
NZ762151A (en) 2017-09-26 2023-10-27 Ecolab Usa Inc Acidic/anionic antimicrobial and virucidal compositions and uses thereof
CA3081597A1 (en) 2018-12-28 2020-06-28 Diversey, Inc. Synergistic disinfectant compositions having enhanced antimicrobial efficacy and stability, and methods of using the same
AU2020262152A1 (en) 2019-04-25 2021-10-28 Universiteit Gent Prebiotic skin care compositions containing carboxylic acids
CN111467338B (en) * 2020-04-07 2021-04-23 中国科学院深圳先进技术研究院 Application of pyroglutamic acid in preparation of medicine for preventing and treating novel coronavirus resistant to new coronary pneumonia
FR3124080A1 (en) * 2021-06-21 2022-12-23 Evergreen Land Limited Antimicrobial topical formulation

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3141821A (en) 1959-03-17 1964-07-21 Lehn & Fink Products Corp Synergistic combination of alkyl sulfonates, alkylaryl sulfonates and topical antibacterial agents for local antisepsis
US3933872A (en) * 1970-02-11 1976-01-20 Ashland Oil, Inc. Method for preparing fatty hydroxamates
GB1407997A (en) 1972-08-01 1975-10-01 Procter & Gamble Controlled sudsing detergent compositions
US4136045A (en) 1976-10-12 1979-01-23 The Procter & Gamble Company Detergent compositions containing ethoxylated nonionic surfactants and silicone containing suds suppressing agents
US4376787A (en) 1979-12-03 1983-03-15 Economics Laboratory, Inc. Control of mastitis
US4828912A (en) 1981-07-20 1989-05-09 Kimberly-Clark Corporation Virucidal product having virucidal and/or germicidal properties
DE3229097A1 (en) 1982-08-04 1984-02-09 Schülke & Mayr GmbH, 2000 Hamburg Microbicidal agents
US5375161A (en) * 1984-09-14 1994-12-20 Accessline Technologies, Inc. Telephone control system with branch routing
FR2601960B1 (en) 1986-07-25 1989-05-26 Lesieur Cotelle DETERGENT, VISCOUS, DILUABLE COMPOSITION AND PROCESS FOR OBTAINING SAME
US5547988B1 (en) 1986-12-23 1997-07-15 Tristrata Inc Alleviating signs of dermatological aging with glycolic acid lactic acid or citric acid
DE3713998A1 (en) 1987-04-27 1988-11-10 Henkel Kgaa CLEANER FOR HARD SURFACES
US4865855A (en) 1988-01-11 1989-09-12 Kimberly-Clark Corporation Antimicrobial absorbent food pad
US5006529A (en) 1988-05-27 1991-04-09 Lever Brothers Company Soap compositions of enhanced antimicrobial effectiveness
WO1991009931A1 (en) 1989-12-29 1991-07-11 The Procter & Gamble Company Ultra mild toilet bar and other personal cleansers
WO1991009924A1 (en) 1989-12-29 1991-07-11 The Procter & Gamble Company Ultra mild surfactant with good lather
US5143720A (en) 1990-11-28 1992-09-01 Microcide, Inc. Disinfecting and sanitizing compositions
DE4140473C2 (en) 1991-12-09 1995-12-21 Schuelke & Mayr Gmbh Skin antiseptic and hand sanitizer
AU3422593A (en) 1992-01-06 1993-08-03 Olin Corporation Biodegradable aqueous filter cleaning composition comprising ethoxylated/propoxylated surfactant, carboxylic acid; and solvent
DE69321461D1 (en) 1992-03-03 1998-11-12 Reginald Keith Whiteley DISINFECTING COMPOSITION
AU671208B2 (en) 1993-06-30 1996-08-15 Colgate-Palmolive Company, The Anti-bacterial cleansing composition
EP0639636B1 (en) 1993-08-19 2001-10-31 Kao Corporation Germicidal-disinfectant detergent composition
AU692478B2 (en) 1993-09-14 1998-06-11 Minnesota Mining And Manufacturing Company Disinfectant composition
US5914300A (en) 1994-06-01 1999-06-22 Lever Brothers Company Mild antimicrobial liquid cleansing formulations comprising hydroxy acid buffering compound or compounds as potentiator of antimicrobial effectiveness
GB9419668D0 (en) 1994-09-28 1994-11-16 Diversey Corp Disinfectant compositions
US5653970A (en) 1994-12-08 1997-08-05 Lever Brothers Company, Division Of Conopco, Inc. Personal product compositions comprising heteroatom containing alkyl aldonamide compounds
CA2206771C (en) 1994-12-09 2007-07-03 Unilever Plc Improvements relating to antimicrobial cleaning compositions
FR2734158B1 (en) 1995-05-17 1997-06-27 Roche Posay Lab Pharma COMBINATION OF A COMPOUND WITH ANTI-MICROBIAL ACTIVITY AND A MONOALKYLETHER OF GLYCEROL
US6110445A (en) 1995-06-26 2000-08-29 Colgate-Palmotive Company Oral composition exhibiting improved uptake and retention of antibacterial compounds on dental tissue surfaces
US5942478A (en) 1995-09-19 1999-08-24 Lopes; John A. Microbicidal and sanitizing soap compositions
AU721868B2 (en) 1995-11-28 2000-07-13 Michael D. Wider Antimicrobial composition and methods of use therefor
GB2309706B (en) * 1996-01-31 2000-02-09 Reckitt & Colman Inc Liquid detergent composition comprising quaternary ammonium surfactant having germicidal properties
ZA974982B (en) 1996-06-06 1998-01-23 Monsanto Co Acidic cleaning compositions containing xanthan gum.
WO1998016192A1 (en) 1996-10-17 1998-04-23 Alterna, Inc. Germicidal composition
JPH10158691A (en) 1996-12-02 1998-06-16 Taisho Pharmaceut Co Ltd Detergent composition
DE19720366A1 (en) 1997-05-15 1998-11-19 Wella Ag Hair cleanser with gloss-enhancing properties
US6190675B1 (en) * 1997-06-04 2001-02-20 Procter & Gamble Company Mild, rinse-off antimicrobial liquid cleansing compositions which provide improved residual benefit versus gram positive bacteria
US5968539A (en) 1997-06-04 1999-10-19 Procter & Gamble Company Mild, rinse-off antimicrobial liquid cleansing compositions which provide residual benefit versus gram negative bacteria
US6210695B1 (en) 1997-06-04 2001-04-03 The Procter & Gamble Company Leave-on antimicrobial compositions
KR20010013377A (en) 1997-06-04 2001-02-26 데이비드 엠 모이어 Mild, leave-on antimicrobial compositions
US6217887B1 (en) 1997-06-04 2001-04-17 The Procter & Gamble Company Leave-on antimicrobial compositions which provide improved immediate germ reduction
US6183757B1 (en) 1997-06-04 2001-02-06 Procter & Gamble Company Mild, rinse-off antimicrobial cleansing compositions which provide improved immediate germ reduction during washing
US6190674B1 (en) 1997-06-04 2001-02-20 Procter & Gamble Company Liquid antimicrobial cleansing compositions
US6287577B1 (en) 1997-11-12 2001-09-11 The Procter & Gamble Company Leave-on antimicrobial compositions which provide improved residual benefit versus gram positive bacteria
US6020375A (en) 1997-06-13 2000-02-01 Senju Pharmaceutical Co., Ltd. Bactericidal composition
US5977041A (en) 1997-09-23 1999-11-02 Olin Microelectronic Chemicals Aqueous rinsing composition
JP3924769B2 (en) 1998-05-12 2007-06-06 味の素株式会社 Hypoallergenic solid detergent
FR2789329B1 (en) 1999-02-05 2001-03-02 Oreal COSMETIC AND / OR DERMATOLOGICAL COMPOSITION CONSTITUTED BY AN OIL-IN-WATER TYPE EMULSION FORMED BY LIPID VESICLES DISPERSE IN AN AQUEOUS PHASE CONTAINING AT LEAST ONE HYDROPHILIC ACID ACTIVE
US6488943B1 (en) 1999-04-13 2002-12-03 The Procter & Gamble Company Antimicrobial wipes which provide improved immediate germ reduction
JP3404337B2 (en) 1999-10-12 2003-05-06 花王株式会社 Aqueous liquid detergent composition
US20040234457A1 (en) 1999-10-19 2004-11-25 The Procter & Gamble Company Methods of preventing and treating SARS using low pH respiratory tract compositions
US6517849B1 (en) 1999-10-19 2003-02-11 The Procter & Gamble Company Tissue products containing antiviral agents which are mild to the skin
AU1096101A (en) 1999-10-19 2001-04-30 Procter & Gamble Company, The Antimicrobial compositions comprising a dicarboxylic acid and a metal salt
HUP0204123A3 (en) 1999-10-19 2003-05-28 Procter And Gamble Co Cincinna Compositions for prevention and treatment of cold and influenza-like symptoms, their preparation and use
AU1095801A (en) 1999-10-19 2001-04-30 Procter & Gamble Company, The Antimicrobial compositions comprising a biologically active organic acid
EP1116788A1 (en) 2000-01-12 2001-07-18 The Procter & Gamble Company Pro-perfume composition
JP2003520809A (en) 2000-01-20 2003-07-08 ザ プロクター アンド ギャンブル カンパニー Antibacterial composition
US20020192407A1 (en) 2001-03-01 2002-12-19 The Procter & Gamble Company Pre-moistened wipe with improved feel and softness
US6610314B2 (en) 2001-03-12 2003-08-26 Kimberly-Clark Worldwide, Inc. Antimicrobial formulations
FR2822377A1 (en) 2001-03-23 2002-09-27 Oreal USE OF FIBERS AS ANTI-IRRITANT AGENT IN A COSMETIC OR DERMATOLOGICAL COMPOSITION
FR2827515B1 (en) 2001-07-20 2005-06-03 Oreal FOAMING COMPOSITION BASED ON SILICA AND CATIONIC POLYMER
US6846846B2 (en) 2001-10-23 2005-01-25 The Trustees Of Columbia University In The City Of New York Gentle-acting skin disinfectants
EP1666073B1 (en) 2004-10-13 2008-08-27 The Procter and Gamble Company Device for delivering an antimicrobial composition

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017501153A (en) * 2013-12-19 2017-01-12 ユニリーバー・ナームローゼ・ベンノートシヤープ Composition
US11814514B2 (en) 2017-12-26 2023-11-14 Lotte Chemical Corporation Thermoplastic resin composition and molded product formed therefrom
CN109609590A (en) * 2018-12-21 2019-04-12 扬州倍加洁日化有限公司 A kind of anti-microbial property test method of wet tissue product

Also Published As

Publication number Publication date
US20090215854A1 (en) 2009-08-27
US20090202463A1 (en) 2009-08-13
US7569530B1 (en) 2009-08-04

Similar Documents

Publication Publication Date Title
US7569530B1 (en) Antimicrobial compositions, products and methods employing same
AU2003243732B2 (en) Antimicrobial compositions, products and methods employing same
US20040001797A1 (en) Antimicrobial compositions, products and methods employing same
US20090035339A1 (en) Methods of Inactivating Viruses
JP3625214B2 (en) Antiseptic disinfectant and cosmetics, pharmaceuticals and foods containing the antiseptic disinfectant
US20060051430A1 (en) Silver dihydrogen citrate compositions
MX2007002762A (en) Silver dihydrogen citrate compositions.
KR20120058571A (en) Use of 1,3-diols as biocides
US20090226384A1 (en) Antimicrobial composition containing triclosan and at least one functionalized hydrocarbon
US20050019355A1 (en) Skin antiseptic and disinfectant
CN113423469A (en) Topical disinfectant compositions
KR20120093173A (en) Use of cycloaliphatic diols as biocides
CN102037989B (en) Aqueous compositions for disinfection and/or sterilization
AU2008200754A1 (en) Antimicrobial compositions, products and methods employing same
KR101320599B1 (en) Antiseptic free and anti-biotic wet tissue
KR20070071337A (en) Wet tissue product having a good antimicrobial property
JP2001302495A (en) Skin-cleansing agent and skin-cleansing supplies
JP7257155B2 (en) skin antiseptic composition
WO2024028179A1 (en) Biocidal composition
JP2022170269A (en) Skin coating formulation with sterilization function
KR20230004974A (en) Antibacterial and Preservative Compositions
KR20230004973A (en) Antibacterial and Preservative Compositions
US20200022363A1 (en) Composition and process delivering a controlled-release agent

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION